Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - HealthWarehouse.com, Inc.Financial_Report.xls
EX-32.2 - EXHIBIT322 - HealthWarehouse.com, Inc.exhibit322.htm
EX-31.2 - EXHIBIT312 - HealthWarehouse.com, Inc.exhibit312.htm
EX-31.1 - EXHIBIT311 - HealthWarehouse.com, Inc.exhibit311.htm
EX-21.1 - EXHIBIT211 - HealthWarehouse.com, Inc.exhibit211.htm
EX-32.1 - EXHIBIT321 - HealthWarehouse.com, Inc.exhibit321.htm

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
_______________________

FORM 10-K
 

x
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
For the Fiscal Year Ended December 31, 2011
   
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
   
For the transition period from _______ to _________.
 
Commission file number 0-13117
 
HEALTHWAREHOUSE.COM, INC.
(Exact name of registrant as specified in its charter)

Delaware
22-2413505
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
 
 
7107 Industrial Road, Florence KY
41042
(Address of principal executive offices)
(Zip Code)
 
Registrant’s telephone number, including area code: (513) 618-0911
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of Class
 
Name of each exchange on which registered
None
 
None

Securities registered pursuant to Section 12(g) of the Act:
 
Common Stock, $.001 par value
(Title of Class)
 
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  o  Yes     x  No
 
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   o  Yes     x  No    
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes x  No ¨
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes   x       No    o
 
 
 
 




 
Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.    o
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “accelerated filer” and “large accelerated filer” in Rule 12b-2 of the Act. (Check one):
 
Large accelerated filer    o     Accelerated filer     ¨     Non-accelerated filer   o Smaller reporting company    x
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).   Yes ¨   No   x
 
The aggregate market value of voting and nonvoting common equity held by non-affiliates, based on the closing price of the common stock, par value $0.001 (the “Common Stock”) on June 30, 2011 of $5.00, as reported on the OTCQB market tier was approximately $21,704,000. Shares of Common Stock held by each officer and director and by each person who owns 5% or more of the outstanding Common Stock have been excluded in that such persons may be deemed to be affiliates. This determination of affiliate status is not necessarily a conclusive determination for any other purpose.
 
There were 10,244,699 shares of Common Stock outstanding as of June 8, 2012.
 
DOCUMENTS INCORPORATED BY REFERENCE:      None
 
 
 
 
 
 
 
 
 
 


 

 
 
 
 
   
Page
     
Item 1.
4
     
Item 1A.
14
     
Item 1B.
24
     
Item 2.
24
     
Item 3.
24
     
Item 4.
25
     
Item 5.
25
     
Item 6.
26
     
Item 7.
26
     
Item 7A. Quantitative and Qualitative Disclosure About Market Risk 31
     
Item 8.
31
     
Item 9.
31
     
Item 9A.
31
     
Item 9B.
33
     
Item 10.
33
     
Item 11.
37
     
Item 12.
40
     
Item 13.
44
     
Item 14.
47
     
Item 15.
48
 
 
 
 
 
 
 


 
 
Information Regarding Forward-Looking Statements
 
This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties, many of which are beyond our control.  Our actual results could differ materially and adversely from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in this report.  Important factors that may cause actual results to differ from any forward-looking statements include any forward-looking statements:
 
·   
significant changes in consumer demand for our products, resulting in volatility of our operating results and financial condition;
 
·   
our ability to effectively respond to changing market conditions;
 
·   
whether as a result of market conditions, or our financial condition or otherwise, the possibility that we will not be able to raise sufficient additional capital needed to operate our business;
 
·   
unexpected costs, lower than expected sales and revenues, and operating deficits;
 
·   
our ability to obtain supply at favorable rates;
 
·   
unexpected changes in our industry’s competitive forces including the manner and degree in which our competitors serve our target market;
 
·   
our ability to attract or retain qualified senior management personnel; and
 
·   
other specific risks that may be referred to in this report including those in Part I, Item 1A, “Risk Factors.”.
 
All statements, other than statements of historical facts, included in this report regarding our strategy, future operations, financial position, estimated revenue or losses, projected costs, prospects and plans and objectives of management are forward-looking statements.  When used in this report, the words “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “plan” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words.  All forward-looking statements speak only as of the date of this report.  We undertake no obligation to update any forward-looking statements or other information contained herein.  Stockholders and potential investors should not place undue reliance on these forward-looking statements.  Although we believe that our plans, intentions and expectations reflected in or suggested by the forward-looking statements in this report are reasonable, we cannot assure stockholders and potential investors that these plans, intentions or expectations will be achieved.  We disclose important factors that could cause our actual results to differ materially from our expectations under “Risk Factors” and elsewhere in this report.  These cautionary statements qualify all forward-looking statements attributable to us or persons acting on our behalf.

Information regarding market and industry statistics contained in this report is included based on information available to us that we believe is accurate. It is generally based on academic and other publications that are not produced for purposes of securities reports or economic analysis.  Forecasts and other forward-looking information obtained from these sources are subject to the same qualifications and the additional uncertainties accompanying any estimates of future market size, revenue and market acceptance of products and services. We have no obligation to update forward-looking information to reflect actual results or changes in assumptions or other factors that could affect those statements. See “Risk Factors” for a more detailed discussion of risks and uncertainties that may have an impact on our future results.

If you are interested in HealthWarehouse.com, Inc. stock, we recommend that, at a minimum, you read the Company's SEC Forms 10-K, 10-Q and 8-K for the past year each filed with the SEC and available at http://www.sec.gov.

 
 
 



 
 
PART I


Recent Developments
 
On April 12, 2012, the Company’s independent registered public accounting firm (the “Auditors”) informed the Board of Directors that it would not be able to complete its audit of the Company’s financial statements for the year ended December 31, 2011 before the Company’s Rule 12b-25 extension for filing its Form 10-K for that period expired.  The Auditors indicated that, primarily due to material weaknesses and other deficiencies in the Company’s control environment, including material weaknesses and other deficiencies that the Company has previously disclosed, they were unable to reach conclusions on unresolved items in their audit.  Although the Auditors had not concluded that an illegal act had occurred, because the Company’s weak control environment and unresolved items suggested a potential for the misappropriation of Company assets, the Auditors recommended that the Board engage an independent third-party to review the unresolved items and assist it with identifying and remediating the control deficiencies.
 
Accordingly, the non-management members of the Board of Directors conducted a review of the unresolved items and control deficiencies identified by the Auditors and related matters (the “Review”) with the assistance of the independent third-party.  Based on the results of the Review, the directors concluded that certain matters identified during the Review required remediation.  These matters are discussed below.
 
·  
Between 2009 and April 2012, an employee who is the son of the managing member of a limited liability company that beneficially owns approximately 12% of the Company’s common stock received advances from the Company in various forms, including the unauthorized provision of fulfillment services at no charge to a business partly owned by a member of his household.  The directors determined that not all these were authorized in accordance with the Company’s policy on related party transactions, documented appropriately or recorded correctly in the Company’s accounting system.  As a result, the Company was not able to monitor the outstanding amount of these advances or ascertain their validity on a continuous basis.  As of December 31, 2011, the balance of these advances totaled $298,707, and additional advances of $73,695 were made in 2012.  The employee has voluntarily resigned from the Company, repaid $235,000 of the outstanding balance, given the Company a demand note, payable after December 1, 2012, for the remaining balance of approximately $140,000, and provided security for his repayment obligation.  See “Related Party Transactions.”
 
·  
The Company’s controls, policies and procedures relating to the use of Company credit cards and Company bank accounts and the reimbursement of employee business expenses were not adequate to ensure that all relevant transactions were authorized in accordance with Company policy, documented appropriately or recorded correctly in the Company’s accounting system.
 
·  
Flaws in the Company’s management information system, including a lack of integration between the systems that report payments and record shipments, and the limited accounting resources available to the Company, prevented the Company from initially reconciling, as of December 31, 2011, accounts used to track timing differences related to amounts due from the Company’s credit card processors, prepaid inventory and inventory that had not been invoiced by the supplier. Such amounts were ultimately reconciled with the assistance of the independent third-party.
 
These items were identified and corrected before the Company issued its financial statements for the year ended December 31, 2011 and therefore did not result in the misstatement of any amounts for that period.  These items also did not materially affect any previously issued financial statements.  The net effect of these items was to increase total assets and to reduce total stockholders’ deficiency by $198,874 in the Company’s consolidated balance sheet as of December 31, 2011, and to decrease net loss by $88,124 in the Company’s consolidated statement of operations for the year ended December 31, 2011.  During the Review, the directors identified material weaknesses and other deficiencies in the Company’s internal controls, and the Company has previously disclosed additional material weaknesses and control deficiencies.  These material weaknesses and other deficiencies in the Company’s internal controls primarily relate to the Company’s need for additional accounting personnel with sufficient supervisory and technical expertise and the Company’s lack of adequate policies, procedures and monitoring in certain areas.  As described in Part II-Item 9A, “Controls and Procedures,” the Company is in the process of implementing a remediation plan to address these deficiencies.
 
 
 


 
 
 
Overview

We are a Verified Internet Pharmacy Practice Sites (“VIPPS”) accredited retail mail-order pharmacy and healthcare e-commerce company that sells discounted generic and brand name prescription drugs, as well as, over-the-counter (OTC) medical products. Our web address is http://www.healthwarehouse.com. At present, we sell:
 
·     
a range of prescription drugs (we are licensed as a mail-order pharmacy for sales to 50 states and the District of Columbia);
 
·     
diabetic supplies including glucometers, lancets, syringes and test strips;
 
·     
OTC medications covering a range of conditions from allergy and sinus to pain and fever to smoking cessation aids;
 
·     
home medical supplies including incontinence supplies, first aid kits and mobility aids; and
 
·     
diet and nutritional products including supplements, weight loss aids, and vitamins and minerals.
 
Our objectives are to make the pharmaceutical supply chain more efficient and to pass the savings on to the consumer.  We are becoming known by consumers as a convenient, reliable, discount provider of over-the-counter products and prescription medications. We intend to continue to expand our product line as our business grows. We are presently licensed as a mail-order pharmacy for sales to 50 states and the District of Columbia.
 
Our customers tend to be uninsured and under-insured consumers who rely on our service for their daily medications.  With many brand name drug patents expiring over the next several years and a general trend of rising insurance co-payments, our service is currently expanding into well-insured and other mainstream consumers of prescription medications, as the market continues to move away from predominantly brand name prescription drugs to generic drugs.  Once the patent on a branded drug has expired, we can typically sell its generic equivalent for less than the purchaser’s insurance co-payment.  Accordingly, we are focused on the cash paying customers and do not accept consumer insurance payment.
 
In March 2007, Hwareh.com, Inc. (“Old HW”), a Delaware corporation formerly named HealthWarehouse.com, Inc., was incorporated to carry on the business of selling OTC products. In November 2007, we began to develop the proprietary software necessary for our business, and in February 2008, version 1.0 of the http://www.healthwarehouse.com website was successfully launched running on our own proprietary software.
 
In March 2008, as part of our expansion into prescription drugs, we completed construction of a full service licensed pharmacy within our warehouse in Loveland, Ohio. This pharmacy passed inspection by the Ohio State Pharmacy Board in April 2008.
 
On May 14, 2009, we completed a share exchange transaction (the “Exchange”) with Clacendix, Inc. (“Clacendix”). At the time, Clacendix existed as a public shell company with no operations that was seeking a target company with which to merge or to complete a business combination.
 
As a result of the Exchange, Old HW became our subsidiary, with Old HW’s former stockholders acquiring approximately 82.4% of the then outstanding shares of our Common Stock.  Effective August 5, 2009, we changed our corporate name to HealthWarehouse.com, Inc., simultaneously with our name change, we changed the corporate name of our subsidiary to Hwareh.com, Inc.  In connection with the name change, we also obtained a new ticker symbol for quotation, and our Common Stock currently trades on the OTCQB Market Tier under the symbol, “QBHEWA.”
 
On July 16, 2010, we filed a Certificate of Amendment to our Certificate of Incorporation with the Secretary of State of the State of Delaware.  The Certificate of Amendment effected a reverse split or combination of our Common Stock of one (1) share for every twenty (20) shares outstanding (the “Reverse Split”).  As a result of the Reverse Split, every twenty (20) shares of Common Stock outstanding before the Reverse Split represents one share of Common Stock after the Reverse Split, with any fractional shares rounded up to the next whole share.  The Certificate of Amendment also reduced the number of authorized shares of the Company’s Common Stock from 750,000,000 to 50,000,000.  Unless otherwise specifically indicated, all share numbers and all share price numbers presented in this Annual Report on Form 10-K have been adjusted to reflect the Reverse Split.
 
 
 

 

 

 
 
On February 14, 2011, Hocks Acquisition Corporation (“Hocks Acquisition”), a wholly-owned subsidiary we formed for the purpose of the acquisition, entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”) with Hocks Pharmacy Inc., an Ohio corporation (“Hocks Pharmacy”),  to purchase, for $200,000 in cash all of the inventory and fixed assets (the “Purchased Assets”) owned by Hocks Pharmacy and used in the operation of its internet pharmacy business (the “Internet Business).  The Internet Business consists primarily of the internet sale of over-the-counter health and medical products and supplies.   That same day, we acquired all of the intangible assets of the Internet Business, including domain names and customer accounts, in a reverse merger of Hocks Acquisition into Hocks.com Inc. (“Hocks.com”), a newly formed Ohio corporation and then wholly-owned subsidiary of Hocks Pharmacy.  The Company determined that certain intangible assets of Hocks, including the domain names and trademarks, have a deminimus value.  Hocks.com Inc. became our wholly-owned subsidiary.
 
On June 15, 2011 the Company commenced a lease on a new facility in Florence, KY. On August 1, 2011. the Company transferred its operations to the new facility. In connection with this move, on February 23, 2012, the Company obtained from the Kentucky Economic Development Finance Authority a commitment for $500,000 and a letter of intent for an additional $500,000 of incentive financing.  The Company must meet certain conditions in order to obtain the full amount of these incentives, including the posting of collateral and the creation of 448 new, full-time jobs for Kentucky residents, half of which must be created in the first two years and maintained for an additional three years after the expiration of the first three year period.

On August 3, 2011, we entered into a Securities Purchase Agreement with three affiliated accredited investors, under which we sold the investors a total of 428,572 shares of our Common Stock at $3.50 per share, for an aggregate price of $1,500,000.  The net proceeds from this sale of Common Stock were used to expand our online presence, upgrade our technology infrastructure, and pay existing indebtedness and accrued expenses, and for general working capital purposes.

On September 2, 2011, we entered into a Loan and Security Agreement (the “2011 Loan Agreement”) with the same two lenders as under the 2010 Loan Agreement (the “Lenders”).  Under the terms of the 2011 Loan Agreement, we borrowed $1,500,000 from each lender for a total of $3,000,000 (the “2011 Loans”).  The 2011 Loans are evidenced by non-convertible, secured promissory notes, bearing interest at 7% per annum, payable at maturity.  The principal amount and all accrued interest on the 2011 Loans are payable on January 15, 2013, or earlier on an event of default or a sale or liquidation of the Company.  In connection with the 2011 Loans, we also granted each Lender a warrant to purchase 250,000 shares of Common Stock at a purchase price of $2.90 per share.  Each warrant may be exercised in whole or in part and from time to time for a term of five years from its grant date.  In addition, from September 2 through September 16, 2011, we sold a total of 168,970 shares of Common Stock to nine accredited investors at a purchase price of $2.90 per share, for an aggregate price of $490,000.  The net proceeds from the 2011 Loans and the additional sales of Common Stock were used to purchase 1,179,212 shares of our Common Stock from Rock Castle Holdings, LLC, a more than 10% stockholder of the Company (“Rock Castle”), which constituted all of the outstanding shares of Common Stock owned by Rock Castle.  The purchase price was $2.90 per share, for an aggregate price of $3,419,715.

On October 17, 2011, we entered into a Securities Purchase Agreement (the “2011 Series C Purchase Agreement”) with three affiliated accredited investors, under which we sold the investors a total of 10,000 newly authorized shares of $0.001 par value Series C Preferred Stock (the “Series C Preferred Stock”) at $100.00 per share, for an aggregate price of $1,000,000. The Series C Preferred Stock has voting rights equal to one vote for each share held, has a liquidation preference equal to its purchase price, has redemption request rights available on or after January 15, 2013, are non-convertible and does not pay dividends. Under the terms of the 2011 Series C Purchase Agreement, we also issued warrants to the investors, pro rata to their investment amounts, to purchase an aggregate of 270,000 shares of the Company’s Common Stock at an exercise price of $2.90 per share.  Each warrant may be exercised in whole or in part and from time to time for a term of five years from its grant date.   The holders of the Series C Preferred Stock are entitled to a preferential liquidating distribution upon the sale or liquidation of the Company equal to the original sale price per share.  The Series C Preferred Stock is not entitled to any dividends, and is not convertible into shares of Common Stock or other capital stock.  The net proceeds from the sale of the Series C Preferred Stock were used to pre-pay principal and accrued interest on the 2011 Loans.

Our Business Model
 
Our business model seeks to improve both the efficiency and convenience by which consumers obtain prescription medications.  To increase efficiency, we make efforts to source products from either the manufacturer or wholesaler level, eliminating unnecessary costs associated with distribution. In addition, we distribute medications to the consumer from a single warehouse, as opposed to retail locations, which we believe eliminates unnecessary costs such as real estate, rents, inventory, and personnel.  By going directly to the consumer via the Internet, we reduce our marketing expense and increase convenience for consumers, especially those taking maintenance medications for conditions ranging from diabetes to high blood pressure.
 
 
 

 
 

 

 
Current Healthcare Distribution Model
Our Distribution
Model
Manufacturer
Manufacturer
Wholesaler
Distributor
HealthWarehouse.com
Pharmacy
Consumer
Consumer

Our target is consumers who are uninsured or underinsured, as well as, elderly patients in the Medicare “donut hole”.  In addition, as insured consumers are seeing co-pays rise, many of our medications can be purchased for cash at prices less than their insurance co-pay.

Our Online Retail Mail-Order Pharmacy
 
We operate a full-service retail mail-order pharmacy within our warehouse in Florence, Kentucky, near Cincinnati, Ohio.  The pharmacy includes two robotic machines, which can each count and package 1,200 prescriptions per day.  Our pharmacy passed inspection by the Kentucky Board of Pharmacy, and we are presently licensed as a mail-order pharmacy for sales to 50 states and the District of Columbia.
 
Our retail mail-order pharmacy offers the following advantages:
 
·        Legitimacy.  We have obtained certifications to separate ourselves from the many uncertified “rogue” pharmacies which exist. We are the 19th pharmacy in the U.S. to receive Verified Internet Practice Sites (VIPPS) certification, issued by the National Board of Pharmacies (NABP). Google, Yahoo, and Bing now all require VIPPS as a requirement to advertise on their sites.
 
·        Convenience.  Our online store is available to consumers 24 hours a day, 7 days a week through the Internet.  We deliver medications free of charge to any location in the United States including Alaska and Hawaii. We offer 6-month and 12-month supplies of medications to reduce the need for refills. All of our products are also available for purchase by phone. We offer additional convenience to our customers through an easy-to-use website, robust search technology, and a variety of features such as multiple checkout options including Google Checkout.
 
·        Selection.  Due to our online structure, we are able to offer a significantly broader assortment of products, with greater depth in each product category, because we do not have the shelf display space limitations of brick-and-mortar drugstores.
 
·        Information.  We provide a broad array of interactive tools and information on our website to help consumers make informed purchasing decisions. Our information services include detailed product information pages, product user manuals and brochures, links to manufacturer websites, detailed product descriptions which contain the manufacturer’s phone number, and customer reviews.  Our customer care representatives are available by phone or email to provide personal guidance and answer customers’ questions.
 
·        Privacy.  When shopping at a “brick-and-mortar” drugstore, many consumers may feel embarrassed or uncomfortable about buying items or asking questions that may reveal personally sensitive aspects of their health or lifestyle to pharmacists, store personnel, or other shoppers.  Our customers avoid these problems by shopping from the privacy of their home or office.
 
 
 
 

 


 
·        Value.  Our goal is to offer shoppers a broad assortment of generic drugs and health products with competitive pricing.  We strive to improve our operating efficiencies and to leverage our fixed costs so that we can pass along the savings to our customers in the form of lower prices and exclusive deals.  Since we source drugs direct from the manufacturer at the wholesale level, we believe that we have lower costs than traditional pharmacies which allows us to provide consumers with the better values.  We also strive to inform customers of additional cost-saving opportunities when they become available.  For example, we show the generic equivalents of all brand name products.
 
·        Customer Service.  Our focus has been on customer service and we endeavor to lead the industry in our policies and procedures.  We currently offer a satisfaction guarantee with what we believe is an industry-leading 90-day return policy with no restocking fees, and 100% free standard shipping on all orders. We are prevented by law from accepting returns for any prescription medication. We received the BizRate Circle of Excellence Award in 2009, 2010 and 2011 for exceptional customer service and satisfaction.
 
Our customer support representatives operate from our call center in Florence, Kentucky.  Our customer support specialists are available 9 a.m. to 8 p.m. Eastern Standard Time, Monday through Friday, via e-mail, fax or telephone to handle customer inquiries and assist customers in finding desired products.  Our online Help Center outlines store policies and provides answers to customers’ frequently asked questions.
 
We ship our products to all 50 states, the U.S. Territories, and APO/FPO military and embassy addresses. We process all orders from our distribution center in Florence, Kentucky near Cincinnati, Ohio. We based our logistics operation there to maintain proximity to UPS, located 90 miles away in Louisville, Kentucky.  Processing from this location allows us to reach up to 80% of the U.S. population by standard ground shipping in two days.  In order to try to maintain high customer satisfaction ratings and quality control over the process, we avoid drop shipping orders.  Due to the relatively short lead time required to fill orders for our products, usually 24 to 48 hours, order backlog has not proven material to our business.
 
Marketing and Sales
 
Our marketing strategy aims to build brand recognition, increase customer traffic to our online store, add new customers, build strong customer loyalty, maximize repeat purchases and develop incremental revenue opportunities.  It is centered on Internet-based advertising.
 
Our online advertising campaigns focus on the following areas:
 
·      Search Engines: Google, Bing and Yahoo;
 
·      Price Comparison Engines: Become, Google Product Search, NexTag, PriceGrabber.com, Pronto, Shopping.com, Shopzilla, Smarter and Yahoo Shopping; and
 
·      Social Networking: Facebook, Foursquare and Twitter.
 
To date, our online advertising has proven to be an effective sales strategy for our business.  Apart from any personnel involved with our online advertising campaigns, we do not have a dedicated sales force.
 
Suppliers
 
There are a number of suppliers available for the pharmaceutical and non-pharmaceutical products that we sell. Our principal suppliers are HD Smith, Amerisource Bergen, Cardinal Health, and Allison Medical, Inc. While we source our supplies from a limited number of suppliers, we do not believe that our business is dependent on any one supplier since the products that we sell are readily available from a number of alternative suppliers.  If a supplier, even if a significant supplier, were to no longer be available to us, we believe that we could source replacement product through one or more alternative suppliers without having a significant effect on our business model.
 
 
 
 


 
 
Customers
 
We sell directly to the individual consumers of the pharmaceutical and non-pharmaceutical products that we sell.  In addition, we work with an insurance company called Easy Choice Health Plan of New York based in New York, NY as well as self-insured companies. We are not dependent on any one or any few major customers.
 
Seasonality
 
Historically, the largest amount of our net sales has occurred during our fourth quarter.  As a result, we sometimes experience an increase in our shipping cost due to complimentary upgrades, split-shipments, and additional long-zone shipments necessary to ensure timely delivery during this time of year.
 
Competition
 
The market for prescription and OTC health products is intensely competitive and highly fragmented.  Our competitors in the segment include chain drugstores, mail order pharmacies, pharmacy benefits managers (PBMs), mass market retailers, warehouse clubs and supermarkets. Many of these potential competitors in the market are also established organizations with greater access to resources and capital than we have. In addition, we face competition from foreign online pharmacies that can often sell drugs to U.S. residents at a lower price because they do not comply with U.S. pharmacy regulations, are not subject to U.S. regulatory oversight, or both. We also compete with Internet portals and online service providers that feature shopping services and with other online or mail-order retailers that offer products similar or the same to those that we sell.
 
We believe that the principal competitive factors in our market includes brand awareness and preference, company credibility, product selection and availability, convenience, price, actual or perceived value, website features, functionality and performance, ease of purchasing, customer service, privacy, quality and quantity of information supporting purchase decisions (such as product information and reviews), and reliability and speed of order shipment.
 
Intellectual Property and Technology
 
We filed for a trademark on the name “HealthWarehouse.com” on August 14, 2007 with the U.S. Patent and Trademark Office, which trademark was granted with a registration date of May 19, 2009.  On February 14, 2011, we acquired the registered trademark “Hocks.com” in connection with our purchase of the online reseller business of Hocks Pharmacy Inc.  We are continuing to use the Hocks.com trademark in connection with the online sale of over-the-counter health and medical supplies.  We also rely on trade secret law and contractual restrictions to protect our intellectual property, and we do not intend to seek patent or copyright protection for our intellectual property at this time.
 
We have implemented a broad array of services and systems for website management, product searching, customer interaction, transaction processing, and order fulfillment functions. These services and systems use a combination of our own proprietary technologies, open-source technologies and commercially-available, licensed technologies.
 
We focus our internal development efforts on creating and enhancing the specialized, proprietary software that is unique to our business.  For example, our core merchandise catalog, as well as our customer interaction, order collection, fulfillment and back-end systems are proprietary to us. Our systems are designed to provide real-time connectivity to our distribution center systems for both pharmacy and OTC products. They include an inventory tracking system, a real-time order tracking system, an executive information system and an inventory replenishment system.
 
Our website at http://www.healthwarehouse.com is hosted on the Amazon EC2 platform (“EC2”) due to the platform’s perceived cost effectiveness and scalability. EC2 allows us to pay only for bandwidth used. In addition, due to Amazon’s lengthy experience at running servers capable of serving one of the largest commerce sites on the web, our site remains scalable on days where our traffic spikes.
 
Our website was developed using 100% open source code. We use a 100% open source platform which runs on Linux, Apache, MySQL and PHP (LAMP).
 
 
 
 


 
 
 
In addition, we have utilized open source software from other vendors to speed up our development time. For management of our content and commerce catalog, we utilize Magento, an open source e-commerce platform.  For our reporting and tools, we utilize Google Analytics. Our checkout process has two options including Google Checkout for OTC orders and our own proprietary checkout for OTC and prescription orders which uses Heartland.
 
Government Regulation
 
Federal and state laws and regulations govern many aspects of our business and are specific to pharmacies and the sale of OTC drugs. Our pharmacy passed inspection by the Kentucky Board of Pharmacy and we are presently licensed as a mail-order pharmacy for sales to 50 states and the District of Columbia. We ship our non-prescription products to all 50 states, the U.S. Territories, and APO/FPO military and embassy addresses.
 
We believe we are in substantial compliance with all existing legal and regulatory requirements material to the operation of our business.  We have standard operating procedures and controls designed to assist in ensuring compliance with existing contractual requirements and state and federal law. We diligently monitor and audit our adherence to these procedures and controls, and we take prompt corrective and disciplinary action when appropriate. However, we cannot predict how courts or regulatory agencies may interpret existing laws or regulations or what additional federal or state legislation or regulatory initiatives may be enacted in the future regarding healthcare or the pharmacy industry, and the application of complex standards to the operation of our business creates areas of uncertainty.
 
In addition, although we presently do not accept insurance reimbursement nor do we participate in federal and state programs such as Medicare and Medicaid, this may change in the future. If in the future we do accept reimbursement from commercial or governmental payors, we would be subject to extensive government regulation including numerous state and federal laws and corresponding regulations directed at preventing fraud and abuse and regulating reimbursement.
 
Among the federal and state laws and regulations that currently affect or may reasonably affect in the future aspects of our business are the following:
 
Regulation of Our Pharmacy Operations.
 
The practice of pharmacy is generally regulated at the state level by state boards of pharmacy. Our pharmacy must be licensed in the state in which it is located. In some states, regulations require compliance with standards promulgated by the United States Pharmacopeia (USP).  The USP creates standards in the packaging, storage and shipping of pharmaceuticals.  Also, many of the states where we deliver pharmaceuticals, including controlled substances, have laws and regulations that require out-of-state mail-order pharmacies to register with that state’s board of pharmacy or similar regulatory body. In addition, some states have proposed laws to regulate online pharmacies, and we may be subject to this legislation if it is passed. Furthermore, if our pharmacy dispenses durable medical equipment items, such as infusion pumps, that bear a federal legend requiring dispensing pursuant to a prescription, we would also be regulated by applicable state and federal durable medical equipment laws.
 
Federal agencies further regulate our pharmacy operations. Pharmacies must register with the Drug Enforcement Administration (DEA) and individual state controlled substance authorities in order to dispense controlled substances. We sell controlled substances and therefore require a DEA license and maintain a DEA license. In addition, the FDA inspects facilities in connection with procedures to effect recalls of prescription drugs. The Federal Trade Commission (FTC) also has requirements for mail-order sellers of goods. The U.S. Postal Service (USPS) has statutory authority to restrict the transmission of drugs and medicines through the mail to a degree that could have an adverse effect on our mail-order operations.  The USPS historically has exercised this statutory authority only with respect to controlled substances. If the USPS restricts our ability to deliver drugs through the mail, alternative means of delivery are available to us.  However, alternative means of delivery could be significantly more expensive. The Department of Transportation has regulatory authority to impose restrictions on drugs inserted in the stream of commerce. These regulations generally do not apply to the USPS and its operations.
 
Additionally, under the Omnibus Budget Reconciliation Act of 1990 and related state and local regulations, our pharmacists are required to offer counseling to our customers about medication, dosage, delivery systems, common side effects, adverse effects or interactions and therapeutic contraindications, proper storage, prescription refill and other information deemed significant by the pharmacists.  We are also subject to requirements under the Controlled Substances Act and federal DEA regulations, as well as related state and local laws and regulations, relating to our pharmacy operations, including registration, security, recordkeeping and reporting requirements related to the purchase, storage and dispensing of controlled substances, prescription drugs and some OTC drugs.
 
 
 
 

 
- 10 -


 
 

 
 
“Compendial standards,” which can also be called “official compendium,” means the standards for drugs related to strength, purity, weight, quality, labeling and packing contained in the USP, official National Formulary, or any supplement to any of them. Under the Food, Drug and Cosmetic Act of 1938, a drug recognized by the Homeopathic Pharmacopeia of the United States must meet all compendial standards and labeling requirements contained therein, or it will be considered adulterated (for example, lacking appropriate strength, quality or purity; or containing poisonous or unsanitary ingredients) or misbranded (for example, having a false or misleading label; or a label containing an inaccurate description of contents).  If we add homeopathic remedies to our product offerings, we will be required to comply with the Food, Drug and Cosmetic Act. The distribution of adulterated or misbranded homeopathic remedies or other drugs is prohibited under the Food, Drug and Cosmetic Act, and violations could result in substantial fines and other monetary penalties, seizure of the misbranded or adulterated items, and/or criminal sanctions.
 
We also are required to comply with the Dietary Supplement Health and Education Act (DSHEA) when selling dietary supplements and vitamins.  The DSHEA generally governs the production, sale and marketing (including labeling) of dietary supplements, and it requires reporting to the FDA of certain adverse events regarding dietary supplements.
 
We believe that our operations have the appropriate licenses required under the laws of the states in which they are located and that we conduct our pharmacy operations in accordance with the laws and regulations of these states.
 
Drug Importation
 
In the face of escalating costs for plan sponsors providing a prescription drug benefit for their employees, and uninsured individuals seeking to lower their drug costs, the issue of importing drugs from Canada or other foreign countries has received significant attention. Drug importation, sometimes called drug re-importation, occurs when prescription medicines from other countries are imported for personal use or commercial distribution. Individual importation activities are generally prohibited under U.S. law, and the FDA has issued warnings and safety alerts to a number of entities seeking to promote or facilitate systematic importation activities.  However, there has been considerable legislative and political activity seeking to change the FDA requirements to enable drug importation, and we are evaluating appropriate actions if such legislation were to be enacted.
 
Health Management Services Regulation
 
All states regulate the practice of medicine and require licensing under applicable state law. It is not our intent to practice medicine and we have tried to structure our website and our business to avoid violation of state licensing requirements.  However, the application of this area of the law to Internet services such as ours is not well established and, accordingly, a state regulatory authority could at some time allege that some portion of our business violates these statutes. Any such allegation could harm our business.  Further, any liability based on a determination that we engaged in the unlawful practice of medicine may be excluded from coverage under the terms of our general liability insurance policy.
 
Consumer Protection Laws
 
Most states have consumer protection laws designed to ensure that information provided to consumers is adequate, fair and not misleading. We believe that our practices conform to the requirements of state consumer protection laws. However, we may be subject to further scrutiny under these laws as they are often interpreted broadly.
 
Regulation Relating to Data Transmission and Confidentiality of Patient Identifiable Information
 
Dispensing of prescriptions and management of prescription drug benefits require the ability to utilize patient-specific information. Government regulation of the use of patient identifiable information has grown substantially over the past several years.  At the federal level, Congress enacted the Health Insurance Portability and Accountability Act of 1996 (HIPAA), which extensively regulates the transmission, use and disclosure of health information by all participants in healthcare delivery, including physicians, hospitals, insurers and other payors.  To the extent that our pharmacy operations engage in certain electronic transactions (including claims for reimbursement by third-party payors), we may be a covered entity which is directly subject to these requirements.  Additionally, regulation of the use of patient-identifiable information is likely to increase. Congress is currently reviewing proposals that would alter HIPAA, which would create additional administrative burdens. Many states have passed or are considering laws addressing the use and disclosure of health information. These proposals vary widely, some relating to only certain types of information, others to only certain uses, and yet others to only certain types of entities.  These laws and regulations have a significant impact on our operations, products and services, and compliance with them is a major operational requirement.  Regulations and legislation that severely restrict or prohibit our use of patient identifiable information could materially adversely affect our business.
 
 
 
 

 
 
- 11 -


 

 
 
Sanctions for failing to comply with HIPAA standards include criminal and civil penalties. If we are found to have violated any state or federal statute or regulation with regard to the confidentiality, dissemination or use of patient medical information, we could be liable for significant damages, fines or penalties.
 
Fraudulent Billing, Anti-Kickback, Stark, Civil Monetary Penalties and False Claims Laws and Regulations
 
Our operations may in the future participate in federal and state programs such as Medicare and Medicaid. If we do, we would be subject to extensive government regulation including numerous state and federal laws and corresponding regulations directed at preventing fraud and abuse and regulating reimbursement. The government’s Medicare and Medicaid regulations are complex and sometimes subjective and therefore may require our management’s interpretation. If we were to participate in federal and state programs such as Medicare and Medicaid, our compliance with Medicare and Medicaid regulations may be reviewed by federal or state agencies, including the Department of Health and Human Services’ (HHS) Office of the Inspector General (OIG), the Centers for Medicare and Medicaid Services (CMS), the Department of Justice (DOJ), and the FDA. To ensure compliance with Medicare, Medicaid and other regulations, government agencies conduct periodic audits to ensure compliance with various supplier standards and billing requirements. Similarly, regional health insurance carriers routinely conduct audits and request patient records and other documents to support claims submitted for payment.
 
Federal law prohibits the payment, offer, receipt or solicitation of any remuneration that is knowingly and willfully intended to induce the referral of Medicare, Medicaid or other federal healthcare program beneficiaries for the purchase, lease, ordering or recommendation of the purchase, lease or ordering of items or services reimbursable under federal healthcare programs. These laws are commonly referred to as anti-remuneration or anti-kickback laws. Several states also have similar laws, known as “all payor” statutes, which impose anti-kickback prohibitions on services covered by any third-party payor (whether or not a federal healthcare program). Anti-kickback laws vary between states, and courts have rarely interpreted them.  If in the future we accept third-party reimbursement, we may be subject to these laws.
 
Courts, the OIG and some administrative tribunals have broadly interpreted the federal anti-kickback statute and regulations.  Courts have ruled that a violation of the statute may occur even if only one of the purposes of a payment arrangement is to induce patient referrals or purchases.  Should we enter the government payor sector, it is possible that our current practices in the commercial sector may not be appropriate in the government payor sector.
 
The Ethics in Patient Referrals Law (Stark Law) prohibits physicians from making a referral for certain Medicare-covered health items or services if they, or their family members, have a financial relationship with the entity receiving the referral. No bill may be submitted in connection with a prohibited referral. Violations are punishable by civil monetary penalties upon both the person making the referral and the provider rendering the service. Such persons or entities are also subject to exclusion from Medicare and Medicaid.  Many states have adopted laws similar to the Stark Law, which restrict the ability of physicians to refer patients to entities with which they have a financial relationship.
 
The Federal False Claims Act prohibits the submission of a false claim or the making of a false record or statement in order to secure a reimbursement from a government-sponsored program. In recent years, the federal government has launched several initiatives aimed at uncovering practices that violate false claims or fraudulent billing laws. Civil monetary penalties may be assessed for many types of conduct, including conduct that is outlined in the statutes above and other federal statutes in this section. Under the Deficit Reduction Act of 2005 (DRA), states are encouraged to pass state false claims act laws similar to the federal statute.
 
Sanctions for fraudulent billing, kickback violations, Stark Law violations or violations of the False Claims Act include criminal and civil penalties. If we do accept third-party reimbursement and/or participate in federal payor programs in the future and are found to have violated any state or federal kickback, Stark Law or False Claims Act law, we could be liable for significant damages, fines or penalties and potentially be ineligible to participate in federal payor programs.
 
 
 
 

 
 
- 12 -


 
 

 
Legislation and Regulation Affecting Drug Prices and Potentially Affecting the Market for Prescription Benefit Plans and Reimbursement for Durable Medical Equipment
 
Recently, the federal government has increased its focus on methods drug manufacturers employ to develop pricing information, which in turn is used in setting payments under the Medicare and Medicaid programs.  One element common to many payment formulas, the use of “average wholesale price” (AWP) as a standard pricing unit throughout the industry, has been criticized as not accurately reflecting prices actually charged and paid at the wholesale or retail level. The DOJ is currently conducting, and the House Commerce Committee has conducted, an investigation into the use of AWP for federal program reimbursement, and whether the use of AWP has inflated drug expenditures by the Medicare and Medicaid programs. Federal and state proposals have sought to change the basis for calculating reimbursement of certain drugs by the Medicare and Medicaid programs.
 
The DRA revised the formula used by the federal government to set the Federal Upper Limit (FUL) for multiple source drugs by adopting 250 percent of the average manufacturer’s price (AMP) without regard to customary prompt pay discounts to wholesalers for the least costly therapeutic equivalent. On July 17, 2006, HHS published a Final Rule for the Medicaid Prescription Drug Program implementing the DRA in which AMP was defined to exclude discounts and rebates to pharmacy benefit managers and include sales to mail-order and specialty pharmacies in the AMP calculation by manufacturers.
 
These proposals and other legislative or regulatory adjustments that may be made to the program for reimbursement of drugs by Medicare and Medicaid, if implemented, could affect our ability to negotiate discounts with pharmaceutical manufacturers. They could also impact the reimbursement we may receive from government payors in the future should we choose to participate in such programs. In addition, they may affect our relationships with health plans. In some circumstances, they might also impact the reimbursement that we would receive from managed care organizations that contract with government health programs to provide prescription drug benefits or otherwise elect to rely on the revised pricing information. Furthermore, private payors may choose to follow the government’s example and adopt different drug pricing bases. This could affect our ability to negotiate with plans, manufacturers and pharmacies regarding discounts and rebates.
 
Relative to our durable medical equipment operations, The Medicare Prescription Drug, Improvement and Modernization Act of 2003 (DIMA), established a program for the competitive acquisition of certain covered items of durable medical equipment, prosthetics, orthotics and supplies (DMEPOS). Diabetes testing supplies, including test strips and lancets, which are commonly supplied via mail-order delivery, are subject to the competitive acquisition program. Only qualified suppliers that meet defined participation standards specified in the final rule will be permitted to engage in the competitive acquisition program. In 2010, mail-order diabetes testing supplies may be subject to a national or regional program, which would require mail-order suppliers to bid on supplying certain DMEPOS items.
 
Medicare Part D and Part B; State Prescription Drug Assistance Programs
 
The DIMA also offers far-reaching changes to the Medicare program. The DIMA established a new Medicare Part D outpatient prescription drug benefit for over 40 million Americans who are eligible for Medicare. Qualified beneficiaries, including senior citizens and disabled individuals, have had the opportunity to enroll in Medicare Part D since January 1, 2006.
 
In addition, many states have expanded state prescription drug assistance programs to increase access to drugs by those currently without coverage and/or supplement the Medicare Part D benefit of those with coverage to offer options for a seamless benefit.  In accordance with applicable CMS requirements, to participate we may have to enter into agreements with a number of state prescription drug assistance programs and collaborate to coordinate benefits with Medicare Part D plans.
 
If we participate in these state and/or federal payor programs in the future, we will have to comply with the applicable conditions of participation for such plans, may be subject to competitive bidding requirements under such plans, and may be subject to adverse pricing limitations imposed by such plans (including the DRA limits described above).
 
Industry Standards for Pharmacy Operations
 
The National Committee on Quality Assurance, the American Accreditation Health Care Commission (known as URAC), the Joint Commission on Accreditation of Healthcare Organizations and other quasi-regulatory and accrediting bodies have developed standards relating to services performed by pharmacies, including mail order, formulary, drug utilization management and specialty pharmacy. While the actions of these bodies do not have the force of law, pharmacy benefit managers and many clients for pharmacy benefit manager services seek certification from them, as do other third parties. These bodies may influence the federal government or states to adopt requirements or model acts that they promulgate. The federal government and some states incorporate accreditation standards of these bodies, as well as the standards of the National Association of Insurance Commissioners and the National Association of Boards of Pharmacy, a coalition of state pharmacy boards, into their drug utilization review regulation. Future initiatives of these bodies are uncertain, and resulting standards or legislation could impose restrictions on us in a manner that could significantly impact our business.
 
 
 


 
- 13 -



 
 
The National Association of Boards of Pharmacy has also developed a program, the Verified Internet Pharmacy Practice Sites, as a model for self-regulation for online pharmacies. We believe we comply with its criteria for certification.

Employees

As of May 31, 2012, we employed 56 full-time employees and 7 part-time employees. The Company at May 31, 2012, had 10 non-contractual laborers. None of our employees are subject to a collective bargaining agreement and we believe that relations with our employees are good. The Company, from time to time, also utilizes independent contractors to supplement its workforce.

 
Risks Related to the Deficiencies in Our Internal Controls and Our Failure to File Timely Periodic Reports with the SEC.
 
We have identified material weaknesses in our internal control over financial reporting, and have concluded that our internal controls were not effective as of December 31, 2011.  We may be unable to remedy these deficiencies or develop, implement and maintain effective controls in future periods.
 
Based on the review conducted by our non-management directors and management’s annual assessment of our internal controls, we have concluded that, as of December 31, 2011, our internal controls over financial reporting were not effective.  The specific material weaknesses identified by the directors and management are described in Part II—Item 9A, “Controls and Procedures”.
 
Although we have initiated a remediation plan to address the material weaknesses and other deficiencies, this plan depends heavily on our hiring additional personnel with appropriate technical accounting and supervisory expertise and receiving interim support from outside professionals.  These measures will require significant financial resources, and our current financial constraints may prevent us from hiring the planned number and quality of personnel, from obtaining the planned guidance from outside professionals or otherwise from fully implementing the remediation plan.
 
Even if we are able to fully implement our remediation plan, we cannot assure you that we will be able to remedy these material weaknesses, that additional material weaknesses or other deficiencies in our internal controls will not arise in the future or that our internal controls will be adequate in all cases to prevent us from reporting inaccurate financial information.  A failure in our internal controls could result in material misstatements in our reported financial information or misappropriation of our assets.  Such failures or misstatements could result in investors losing confidence in our reported financial information, which may adversely affect the market price of our common stock or restrict our ability to raise capital.  In addition, we may be subject to investigations by or sanctions from the SEC or other governmental authorities and lawsuits from investors, all of which could adversely affect our results of operations.
 
Our failure to file our Form 10-K for the year ended December 31, 2011 and our Form 10-Q for the quarter ended March 31, 2012 with the SEC on time limits our access to the public securities markets, and if we fail to make timely filings in the future we could be removed from the OTCQB Market Tier, which could adversely affect the liquidity of our common stock.
 
We did not file this Form 10-K with the SEC on time and we have not yet filed our Form 10-Q for the quarter ended March 31, 2012, which was due on May 15, 2012.  As a consequence, we will be ineligible to use short form registration statements, such as Form S-3, to register securities for sale until we have been timely in filing our periodic reports under the Exchange Act for twelve months.  Although we still may register securities using Form S-1, the extra time and expense of using this form is likely to increase our cost of raising capital in the public markets and may limit our ability to respond quickly to market opportunities.
 
 
 
 
 

 
- 14 -



 
In order to maintain price quotation privileges for our common stock on the OTCQB Market Tier, we must file our periodic reports under the Exchange Act on time.  Although the delay in filing our Form 10-K for the year ended December 31, 2011 and our Form 10-Q for the quarter ended March 31, 2012 have not resulted in the loss of our quotation privileges, if we are delinquent in making future filings, our shares may be removed from the OTCQB Market Tier.  If our shares are removed from quotation, the liquidity for our common stock could be adversely affected by reducing the ability or willingness of broker-dealers to make a market in or otherwise sell our shares and the ability of our shareholders to sell their shares in the secondary market.
 
Risks Relating to Our Business and Industry
 
We have a limited operating history, a history of generating significant losses, we have a substantial working capital deficiency and a stockholders’ deficiency; and may not be able to sustain profitability. The report of our independent registered public accounting firm contains an explanatory paragraph that expresses substantial doubt about our ability to continue as a going concern.
 
Old HW, which now constitutes our principal business, was formed in March 2007 and has a limited operating history upon which you can evaluate our business and prospects. To date, we have not been profitable, and we may never achieve profitability on a full-year or consistent basis. We incurred net losses of $5,712,199 for the year ended December 31, 2011 and $3,691,674 for the year ended December 31, 2010. The report of our independent registered public accounting firm with respect to our financial statements as of December 31, 2011  and for the year then ended indicates that our financial statements have been prepared assuming that we will continue as a going concern.  The report states that, we have incurred significant operating losses and we need to raise additional funds to meet our obligations and sustain operations.  These conditions raise substantial doubt about our ability to continue as a going concern.  Our plans in regard to these matters are described in footnote 2 to our audited financial statements as of December 31, 2011 and for the year then ended.  Our financial statements do not include any adjustments that might result from the outcome of this uncertainty. If our plans or assumptions change or prove to be inaccurate, we may continue to incur net losses in 2012, and possibly longer.  As a result, investors may lose all or a part of their investment.
 
We may experience significant fluctuations in our operating results and rate of growth.
 
Our evolving business model and the unpredictability of our industry make it difficult for us to forecast accurately the level or source of our revenues and our rate of growth. Our financial projections are based on assumptions and estimates that inherently are subject to significant business, economic, competitive, regulatory and operational uncertainties, contingencies and risks, many of which are beyond our control. Our projections assume the success of our business strategy. The success of this strategy is subject to uncertainties and contingencies beyond our control, and we cannot assure you that the strategy will be successful or that the anticipated benefits from the strategy will be realized in the manner or during the periods reflected in our projections or at all. These uncertainties may result in material changes in our financial condition and results of operations, which may differ materially from our projections.
 
Our revenues and operating results may vary significantly from quarter to quarter.
 
Our revenues and operating results may vary significantly from quarter to quarter due to a number of factors, including:
 
·     
our ability to retain and increase sales to existing customers, attract new customers, and satisfy our customers’ demands;
 
·     
the frequency and size of customer orders and the quantity and mix of OTC and prescription products our customers purchase;
 
·     
changes in demand with respect to existing and new OTC and prescription products;
 
·     
changes in consumer acceptance and usage of the Internet, online services, and e-commerce;
 
 
 
 

 
 
- 15 -



 
·     the price we charge for our OTC and prescription products and for shipping those products, or changes in our pricing policies or the pricing policies of our competitors;
 
·     the extent to which we offer free shipping or other promotional discounts to our customers;
 
·     our ability to acquire merchandise, manage inventory, and fulfill orders;
 
·     technical difficulties, system downtime, or interruptions;
 
·     timing and costs of upgrades and developments in our systems and infrastructure;
 
·     timing and costs of marketing and other investments;
 
·     disruptions in service by shipping carriers;
 
·     the introduction by our competitors of new websites, products, or services;
 
·     the extent of reimbursements available from third-party payors; and
 
·      changes in government regulation.
 
In addition, our operating expenses are largely based on anticipated revenue trends and a high percentage of our expenses are fixed in the short term.  As a result, a delay in generating or recognizing revenue for any reason could result in substantial additional operating losses.
 
We face significant competition from both traditional and online domestic pharmaceutical and medical product retailers.
 
The market segments in which we compete are rapidly evolving and intensely competitive, and we have many competitors in different industries, including both the retail and e-commerce services industries. These competitors include chain drugstores, mass market retailers, warehouse clubs, supermarkets, specialty retailers, major department stores, insurers and health care providers, mail-order pharmacies, Internet portals and online service providers that feature shopping services, and various online stores that offer products within one or more of our product categories. Many of our current and potential competitors have longer operating histories, larger customer bases, greater brand recognition, and significantly greater financial, marketing, and other resources than we have.  They may be able to secure merchandise from vendors on more favorable terms, operate with a lower cost structure, adopt more aggressive pricing policies, or devote more resources to technology development and marketing than we do. In addition, other companies in the retail and e-commerce service industries may enter into business combinations or alliances that would strengthen their competitive positions and prevent them, their affiliated companies, or their strategic partners from entering into relationships with us. For example, our inability to enter into or maintain relationships with major insurance companies or managed care organizations could be a major competitive disadvantage to us.
 
We face competition from online pharmacies outside the United States.
 
Although it is currently illegal to re-import prescription drugs into the United States from any foreign country, we nonetheless face competition from online pharmacies outside the United States. A growing number of U.S. consumers seek to fill their prescriptions through Canadian and other foreign online pharmacies, and a number of state and local governments have set up websites directing their constituents to Canadian pharmacies. The FDA has taken only limited action to date, and may not take aggressive action in the future, against those who illegally re-import prescription drugs or support or facilitate illegal re-importation.  In the U.S. Congress, legislation allowing for re-importation of prescription drugs by individuals for personal use has repeatedly been introduced.  If such legislation were to be enacted, or if consumers increasingly use foreign-based online prescription drug websites instead of U.S.-based online pharmacies, such as ours, to fill their prescription needs, our business and operating results could be harmed.
 
 
 

 
- 16 -



 
 
We may be unable to increase the migration of consumers of health and pharmacy products from brick-and-mortar stores to our online solution, which would harm our revenues and prevent us from becoming profitable.
 
If we do not attract and retain higher volumes of customers to our Internet store at a reasonable cost, we will not be able to increase our revenues or achieve consistent profitability. Our success depends on our ability to continue to convert a large number of customers from traditional shopping methods to online shopping for health and pharmacy products. Specific factors that could prevent widespread customer acceptance of our online solution include:
 
·     
shipping charges, which do not apply to purchases made at a “brick-and-mortar” store;
 
·     
delivery time associated with Internet orders, as compared to the immediate receipt of products at a brick-and-mortar store;
 
·     
lack of consumer awareness of our website;
 
·     
additional steps and delays in verifying prescriptions and ensuring insurance coverage for prescription products;
 
·     
non-participation in the networks of some insurance carriers;
 
·     
regulatory restrictions or reform at the state and federal levels that could affect our ability to serve our customers;
 
·     
the general acceptance or legalization of prescription drug re-importation;
 
·     
customer concerns about the security of online transactions, identity theft, or the privacy of their personal information;
 
·     
product damage from shipping or shipments of wrong or expired products from us or other vendors, resulting in a failure to establish, or loss of, customers’ trust in buying drugstore items online;
 
·     
inability to serve the acute care needs of customers, including emergency prescription drugs and other urgently needed products;
 
·     
delays in responses to customer inquiries;
 
·     
difficulties or delays in returning or exchanging orders; and
 
·     
activity that diminishes a user’s online experience or subjects online shoppers to security risks, such as viruses, spam, spyware, phishing (spoofing e-mails directed at Internet users), “denial of service” attacks directed at Internet service providers and online businesses, and breaches of data security.
 
Changing competitive forces within the healthcare industry may adversely affect our ability to obtain and sustain a competitive advantage.
 
In recent years, pharmaceutical suppliers have been subject to increasing consolidation. As a result, a small number of very large companies control a significant share of the market. Accordingly, we depend on fewer suppliers for our products and therefore we may be less able to negotiate price terms with suppliers. Many healthcare organizations also have consolidated to create larger healthcare enterprises with greater market power. If this consolidation trend continues, it could reduce the size of our target market and give the resulting enterprises greater bargaining power, which may lead to erosion of the prices for our products and services.  Additionally, erosion of our competitive advantage may result from increased competition in our target market through supply and distribution methods similar to our own by those companies with which we currently compete but who have a more established operating history.  Furthermore, changes in the healthcare industry’s or our pharmaceutical suppliers’ pricing, selling, inventory, distribution or supply policies or practices could significantly reduce our revenues and net income.
 
 
 

 
 
- 17 -



 
 
If our marketing efforts are not effective at attracting and retaining customers at an acceptable cost, we will be unable to achieve profitability.
 
If we do not maintain our brand and continue to increase awareness of our Internet shopping presence, we may not build a critical mass of customers. Promoting and positioning our brand depends largely on the success of our marketing efforts and our ability to provide consistent, high quality customer experiences. We believe that, because we are a small company with low public brand awareness, achieving significant market awareness will require significant marketing expense. To promote our brand and our products and services, we have incurred and expect to continue to incur substantial expense in our marketing efforts both to attract and to retain customers. Our promotional activities may not be effective at building our brand awareness and customer base to the extent necessary to generate sufficient revenue to become consistently profitable. Search engine and other online marketing initiatives comprise a substantial part of our marketing efforts, and our success depends in part on our ability to manage costs associated with these initiatives, or to find other channels to acquire and retain customers cost-effectively. The demand for and cost of online advertising has been increasing and may continue to increase.  An inability to acquire and retain customers at a reasonable cost would increase our operating costs and prevent us from achieving profitability.
 
Our profitability can be adversely affected by a decrease in the introduction of new brand name and generic prescription drugs.

Our sales and profit margins are materially affected by the introduction of new brand name and generic drugs.  New brand name drugs can result in increased drug utilization and associated sales revenues, while the introduction of lower priced generic alternatives typically result in higher gross profit margins, due to the fact, the Company is able to purchase the generic drugs on a much more competitive cost basis.  Accordingly, a decrease in the number of significant new brand name drugs or generics successfully introduced could adversely affect our results of operations.
 
Since our business is Internet-based, we are vulnerable to system interruption and damage, which would harm our operations and reputation.
 
Our ability to receive and fulfill orders promptly and accurately is critical to our success and largely depends on the efficient and uninterrupted operation of our computer and communications hardware and software systems. We experience periodic system interruptions that impair the performance of our transaction systems or make our website inaccessible to our customers. These systems interruptions delay us from efficiently accepting and fulfilling orders, sending out promotional e-mails and other customer communications in a timely manner, introducing new products and features on our website, promptly responding to customers, or providing services to third parties.  Frequent or persistent interruptions in our services could cause current or potential customers to believe that our systems are unreliable, which could cause them to avoid our website, drive them to our competitors, and harm our reputation. To minimize future system interruptions, we need to continue to add software and hardware and to improve our systems and network infrastructure to accommodate increases in website traffic and sales volume, to replace aging hardware and software, and to make up for two years of underinvestment in technology. We may be unable to promptly and effectively upgrade and expand our systems and integrate additional functionality into our existing systems. Any unscheduled interruption in our services could result in fewer orders, additional operating expenses, or reduced customer satisfaction, any of which would harm our revenues and operating results and could delay or prevent our becoming consistently profitable. In addition, the timing and cost of upgrades to our systems and infrastructure may substantially affect our ability to achieve or maintain profitability.
 
All of our fulfillment operations and inventory are located in our distribution facility, and any significant disruption of this center’s operations would hurt our ability to make timely delivery of our products.
 
We conduct all of our fulfillment operations from our distribution facility in Florence, Kentucky, which houses our entire product inventory.  A natural disaster or other catastrophic event, such as an earthquake, fire, flood, severe storm, break-in, server or systems failure, terrorist attack, or other comparable event at this facility, would cause interruptions or delays in our business and loss of inventory and could render us unable to process or fulfill customer orders in a timely manner, or at all.  Further, we have no formal disaster recovery plan, and our business interruption insurance may not adequately compensate us for losses that may occur.  In the event that a significant part of this facility was destroyed or our operations were interrupted for any extended period of time, our business, financial condition, and operating results would be harmed.
 
 
 

 
- 18 -



 
 
Our operating results will be harmed if we are unable to manage and sustain our growth.
 
Our business is unproven on a large scale and actual operating margins may be less than expected. If we are unable to scale capacity efficiently, we may fail to achieve expected operating margins, which would have an adverse effect on our operating results.
 
If we are unable to obtain shipments of products from our vendors, our business and results of operations would be harmed.
 
We have significant vendors that are important to our sourcing of pharmaceutical and non-pharmaceutical products. We do not have long-term arrangements with most of our vendors to guarantee availability of merchandise, particular payment terms, or extension of credit limits. If our current vendors were to stop selling merchandise to us on acceptable terms, we may not be able to acquire merchandise from other vendors in a timely and efficient manner and on acceptable terms, or at all.
 
We have significant inventory risk.
 
We must maintain sufficient inventory levels to operate our business successfully and to meet our customers’ expectations that we will have the products they order in stock. However, we must also guard against the risk of accumulating excess inventory.  We are exposed to significant inventory risk as a result of rapid changes in product cycles, changes in consumer tastes, uncertainty of success of product launches, seasonality, manufacturer backorders, and other vendor-related problems. In order to be successful, we must accurately predict these trends and events, which we may be unable to do, and avoid over- or under-stocking products. In addition, demand for products can change significantly between the time product inventory is ordered and the time it is available for sale. When we begin selling a new product, it is particularly difficult to forecast product demand accurately. A failure to optimize inventory would increase our expenses if we have too much inventory, and would harm our margins by requiring us to make split shipments for backordered items or pay for expedited delivery from the manufacturer if we had insufficient inventory. In addition, we may be unable to obtain certain products for sale on our website as a result of general shortages (for example, in the case of some prescription drugs), manufacturer policies (for example, in the case of some contact lenses and prestige beauty items), manufacturer or distributor problems, or popular demand. Failure to have inventory in stock when a customer orders it could cause us to lose that order or that customer. The acquisition of some types of inventory, or inventory from some of our sources, may require significant lead time or prepayment, and this inventory may not be returnable. We carry a broad selection of products and significant inventory levels of a substantial number of products, and we may be unable to sell this inventory in sufficient quantities or during the relevant selling seasons.  The occurrence of one or more of these inventory risks may adversely affect our business and operating results.
 
If we make an error in filling or packaging the prescription drugs that we sell, we would be subject to liability and negative publicity.
 
Errors relating to prescriptions, dosage, and other aspects of the prescription medication could result in liability for us that our insurance may not cover. Because we distribute pharmaceutical products directly to the consumer, we are one of the most visible participants in the distribution chain and therefore have increased exposure to liability claims. Our pharmacists are required by law to offer counseling, without additional charge, to our customers about medication, dosage, delivery systems, common side effects, and other information deemed significant by the pharmacists. Our pharmacists may have a duty to warn customers regarding any potential adverse effects of a prescription drug if the warning could reduce or negate those effects. This counseling is in part accomplished through e-mails to our customers and inserts included with the prescription, which may increase the risk of miscommunication because the customer is not personally present to receive the counseling or advice or may not have provided us with all relevant information. Although we also post product information on our website, customers may not read this information. Providing information on pharmaceutical and other products creates the potential for claims to be made against us for negligence, personal injury, wrongful death, product liability, malpractice, invasion of privacy, or other legal theories based on our product or service offerings. Our general liability and business owners’ liability insurance may not cover potential claims of this type or may not be adequate to protect us from all liabilities that may be imposed if any such claims were to be successful. In addition, errors by either us or our competitors may also produce significant adverse publicity either for us or for the online pharmacy industry in general, which could result in an immediate reduction in the amount of orders we receive and would harm our ability to conduct and sustain our business.
 
 
 
 

 
 
- 19 -



 
 
Security breaches would damage our reputation, expose us to liability and otherwise harm our business.
 
Our security measures may not prevent security breaches that could harm our business. To succeed, we must provide a secure transmission of confidential information over the Internet and protect the confidential customer and patient information we retain, such as credit card numbers and prescription records. A third party who compromises or breaches the physical and electronic security measures we use to protect transaction data and customer records could misappropriate proprietary information, cause interruptions in our operations, damage our computers or those of our customers, or otherwise harm our business. Any of these would harm our reputation and expose us to a risk of loss or litigation and possible liability. We may need to expend significant resources to protect against security breaches or to address problems caused by breaches.
 
Expanding the breadth and depth of our product offerings is expensive and difficult, and we may receive no benefit from our expansion.
 
We intend to continue to expand the breadth and depth of our prescription and OTC product offerings by promoting new or complementary products or sales formats. Expansion of our offerings in this manner could require significant additional expenditures and could strain our management, financial, and operational resources. For example, we may need to incur significant marketing expenses, develop relationships with new fulfillment partners or manufacturers, or comply with new regulations. We may be unable to expand our product offerings or sales formats in a cost-effective or timely manner, and any new offerings or formats may not generate satisfactory revenues to offset the costs involved. Furthermore, any new product offering or sales format that is not favorably received by consumers could damage the reputation of our brand. A lack of market acceptance of our efforts or our inability to generate sufficient revenues to offset the cost of expanded offerings would harm our business.
 
The implementation of the Medicare Part D prescription drug benefit has and will likely continue to adversely affect drug pricing, which decreases our profitability.
 
In 2006, the Medicare Part D prescription drug benefit under the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (“DIMA”) became effective. The Medicare Part D prescription drug benefit has negatively affected, and is likely to continue to have a negative impact on, our business. Medicare Part D prescription drug coverage will likely increase the number of senior citizens with prescription drug coverage and reduce the number of customers who pay for their prescription drugs themselves. Customers who choose to obtain coverage under a Medicare Part D plan will likely purchase fewer drugs, or no longer purchase drugs, from us. Because we are not currently processing claims for Medicare Part D, we will be able to serve Medicare D customers only when those customers elect to purchase outside of their Medicare Part D plan and purchase their prescriptions out-of-pocket, such as when the particular medication is not covered by the customer’s Medicare plans or when the customer’s purchase is not covered because of a deductible, co-payment, or other exclusion. Moreover, the DIMA calls for significant changes to the formulas the Medicare program uses to calculate its payments for prescription drugs, as well as introduction of managed care elements and changes to the administration of the drug benefit program. When fully implemented, these changes could exert downward pressure on prescription drug prices and payments by the government, even as the number of people who use the Medicare benefits to pay for prescription drugs increases. All of these factors could adversely affect our drug prices and dispensing fees, and ultimately could reduce our profit margins.
 
Government regulation of our business is extensive, and our failure to comply fully with regulations could result in civil and criminal penalties for us.
 
Our business is subject to extensive federal, state and local regulations.  For example:
 
·     
entities engaging in the practice of pharmacy are subject to numerous federal and state regulatory requirements, including those relating to pharmacy licensing and registration, the dispensing of prescription drugs, pharmacy record keeping and reporting, and the confidentiality, security, storage, and release of patient records; and
 
·     
the sale, advertisement, and promotion of, among other things, prescription, OTC and homeopathic medications, dietary supplements, medical devices, cosmetics, foods, and other consumer products that we sell are subject to regulation by the FDA, the FTC, the Consumer Product Safety Commission, and state regulatory authorities, as the case may be.
 
 
 

 
 
- 20 -


 

 
 
As we expand our product offerings and more non-pharmaceutical products become subject to FDA, FTC and other regulation, more of our products will likely be subject to regulation. In addition, regulatory requirements to which our business is subject may expand over time, and some of these requirements may have a disproportionately negative effect on Internet pharmacies.  For example, the federal government and a majority of states now regulate the retail sale of OTC products containing pseudoephedrine that might be used as precursors in the manufacture of illegal drugs. As a result, we are currently unable to sell these products to customers residing in states that require retailers to obtain a physical form of identification or maintain a signature log. Some members of Congress have proposed additional regulation of Internet pharmacies in an effort to combat the illegal sale of prescription drugs over the Internet, and state legislatures could add or amend legislation related to the regulation of nonresident pharmacies. In addition to regulating the claims made for specific types of products, the FDA and the FTC may attempt to regulate the format and content of websites that offer products to consumers. The laws and regulations applicable to our business often require subjective interpretation, and we cannot be certain that our efforts to comply with these regulations will be deemed sufficient by the appropriate regulatory agencies. Violations of any regulations could result in various civil and criminal penalties, including suspension or revocation of our licenses or registrations, seizure of our inventory, or monetary fines, any of which could harm our business, financial condition, or operating results. Compliance with new laws or regulations could increase our expenses or lead to delays as we adjust our website and operations.
 
Increasing concern about privacy, spam, and the use and security of customer information could restrict our marketing efforts and harm our business.
 
Internet retailers are also subject to increasing regulation and scrutiny relating to privacy, spam, and the use and security of personal user information. These regulations, along with increased governmental or private enforcement (for example, by Internet service providers), may increase the cost of growing our business. Current and proposed regulations and enforcement efforts may restrict our ability to collect and use demographic and personal information from users and send promotional e-mails, which could be costly or harm our marketing efforts. For example, if one or more Internet service providers were to block our promotional e-mails to customers, our ability to generate orders and revenue could be harmed. Further, any violation of privacy, anti-spam, or data protection laws or regulations may subject us to fines, penalties, and damages and may otherwise have a material adverse effect on our business, results of operations, and financial condition.
 
If people or property is harmed by the products we sell, product liability claims could damage our business and reputation.
 
Some of the products we sell may expose us to product liability claims relating to personal injury, death, or property damage caused by these products and may require us to take actions such as product recalls. Any such product liability claim or product recall may result in adverse publicity regarding us and the products we sell, which may harm our reputation. If we are found liable under product liability claims, we could be required to pay substantial monetary damages. Further, even if we successfully defend ourselves against this type of claim, we could be forced to spend a substantial amount of money in litigation expenses, our management could be required to spend valuable time in the defense against these claims, and our reputation could suffer, any of which could harm our business. Our current vendors do not, and future vendors may not, indemnify us against product liability. Further, our liability insurance may not be adequate to protect us from all liability that may be imposed as a result of these claims, and we cannot be certain that insurance will continue to be available to us on economically reasonable terms, or at all. Any imposition of product liability that is not covered by vendor indemnification or our insurance could harm our business, financial condition, and operating results.  We do not have vendor indemnification clauses with our current vendors.
 
If we are required to collect sales and use taxes on the products we sell in additional jurisdictions, we may be subject to liability for past sales and our future sales may decrease.
 
In accordance with current industry practice, historically we have not collected sales and use taxes or other taxes with respect to shipments of goods into states other than Kentucky and Nevada. The operation of our distribution center, the operations of any future distribution centers and other aspects of our evolving business, however, may result in additional sales and use tax collection obligations.  In addition, one or more other states may successfully assert that we should collect sales and use or other taxes on the sale of our products in that state. One or more states or the federal government may seek, either through unilateral action or through federal legislation, to impose sales or other tax collection obligations on out-of-jurisdiction companies that engage in electronic commerce as we do.  Moreover, one or more states could begin to impose sales taxes on sales of prescription products, which are not generally taxed at this time, or impose sales taxes on sales of certain prescription products. The imposition of additional tax obligations on our business by state and local governments could create significant administrative burdens for us, decrease our future sales, and harm our cash flow and operating results.
 
 
 

 
- 21 -


 

 
 
We are dependent on key personnel and their loss would adversely affect our ability to conduct our business.
 
In order to execute our business plan, we must be able to keep our existing management and professionals and, when necessary, hire additional personnel who have the expertise we need. We cannot assure you that we will be able to this, and our failure to do so could have a material adverse effect on our business, results of operations and financial condition. We are particularly dependent on the services of Lalit Dhadphale, our Chief Executive Officer and President. We do not carry key-man life insurance for our benefit on Mr. Dhadphale or on any other employee of our company.
 
We are a public company and, as such, are subject to the reporting requirements of federal securities laws, which are expensive and may divert resources from other projects, thus impairing our ability to grow.
 
We are a public reporting company and, accordingly, are subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and other U.S. federal securities laws, including compliance with the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”). Compliance with these obligations requires significant time and resources from our management and increases our legal, insurance and financial compliance costs. It is also time consuming and costly for us to develop and implement the internal controls and reporting procedures required by Section 404 of the Sarbanes-Oxley Act. If we are unable to comply with the requirements of the Sarbanes-Oxley Act, it may preclude us from keeping our filings with the SEC current. Non-current reporting companies may be subject to various restrictions, such as the inability to be quoted on the OTCQB Market Tier.  See “If we fail to remain current in our reporting requirements, we could be removed from the OTCQB Market Tier, which would limit the ability of broker-dealers to sell our securities and the ability of our shareholders to sell their securities in the secondary market.” ( As of April 16, 2012, when the Company failed to file the SEC Form 10-k on a timely basis has been trading on a pink sheet basis.)
 
Risks Related to Our Common Stock
 
Our common stock may be considered a “penny stock” and may be difficult to sell.
 
The SEC has adopted regulations which generally define “penny stock” to be an equity security that has a market or exercise price of less than $5.00 per share, subject to specific exemptions. The market price of our common stock has been below $5.00 per share and therefore we are designated as a “penny stock” according to SEC rules. This designation requires any broker or dealer selling these securities to disclose certain information concerning the transaction, obtain a written agreement from the purchaser and determine that the purchaser is reasonably suitable to purchase the securities. These rules restrict the ability of brokers or dealers to sell our common stock and may affect the ability of our stockholders to sell their shares. In addition, since our common stock is quoted on the OTCQB Market Tier, our stockholders may find it difficult to obtain accurate quotations of our common stock and may find few buyers to purchase the stock or a lack of market makers to support the stock price.
 
Our stock price may continue to be volatile and may decrease in response to various factors, which could adversely affect our business and cause our stockholders to suffer significant losses.
 
Our common stock is illiquid, and its price has been and may continue to be volatile in the indefinite future.  During 2011, the high and low sale prices of our common stock were $6.90 and $2.75, respectively.  The price of our stock could fluctuate widely in response to various factors, many of which are beyond our control, including the following:
 
·    changes in our industry;
 
·    government regulations;
 
·    competitive pricing pressures;
 
·    our ability to obtain working capital;
 
·    additions or departures of key personnel;
 
 
 
 

 
- 22 -


 

 
 
·    limited “public float” in the hands of a small number of persons, whose sales or lack of sales could result in positive or negative pricing pressure on the market price for our common stock;
 
·    sales of our common stock;
 
·    our ability to execute our business plan;
 
·    operating results that fall below expectations;
 
·    loss of any strategic relationship;
 
·    economic and other external factors; and
 
·    period-to-period fluctuations in our financial results.
 
In addition, the securities markets have from time to time experienced significant price and volume fluctuations that are unrelated to the operating performance of particular companies. These market fluctuations may also materially and adversely affect the market price of our common stock.
 
If we fail to remain current in our reporting requirements, we could be removed from the OTCQB Market Tier, which would limit the ability of broker-dealers to sell our securities and the ability of our shareholders to sell their securities in the secondary market.
 
Companies trading on the OTCQB Market Tier, such as us, must be reporting issuers under Section 12 of the Exchange Act, and must be current in their reports under Section 13 of the Exchange Act, in order to maintain price quotation privileges on the OTCQB Market Tier. If we fail to remain current in our reporting requirements, we could be removed from the OTCQB Market Tier. As a result, the market liquidity for our securities could be adversely affected by limiting the ability of broker-dealers to sell our securities and the ability of our shareholders to sell their securities in the secondary market. See “We must comply with Section 404 of the Sarbanes-Oxley Act, which requires us to document and test our internal controls over financial reporting.  Any delays or difficulty in satisfying these requirements could adversely affect our future stock price.”
 
Our stock trading volume may not provide adequate liquidity for investors, and the price of our common stock may fluctuate significantly.  This may make it difficult for you to resell our common stock when you want or at prices you find attractive.

Shares of our common stock are traded on the over-the-counter markets, including the OTCQB Market Tier of the OTC Markets Group Inc. (formerly the Pink Sheets).  The average daily trading volume in our common stock is generally less than that of larger companies whose stocks are listed on an exchange and can often be sporadic and very limited.  Given the limited and sporadic trading of our common stock, holders of our common stock may be unable to make significant sales of the common stock in a brief period of time.  In addition, our common stock may be subject to significant price swings even when a relatively small number of shares are traded.  We cannot predict the volume or prices at which our common stock will trade in the future.

Our officers, directors and 5% or greater stockholders have significant voting power.
 
Our executive officers, directors, and our 5% or greater stockholders beneficially own approximately 62% of our outstanding voting securities.  If these stockholders act together, they will be able to exert significant control over our management and affairs requiring stockholder approval, including approval of significant corporate transactions.
 
 
 
 

 
 
- 23 -



 
 
 
We could issue “blank check” preferred stock without stockholder approval with the effect of diluting then current stockholder interests and impairing their voting rights and provisions in our charter documents could discourage a takeover that stockholders may consider favorable.
 
 Our certificate of incorporation authorizes the issuance of up to 1,000,000 shares of “blank check” preferred stock with designations, rights and preferences as may be determined from time to time by our board of directors. To date, we have designated 200,000 of these shares as Series A Convertible Preferred Stock, 625,000 of these shares as Series B Convertible Preferred Stock, and 10,000 of these shares as Series C Preferred Stock, leaving 165,000 shares of “blank check” preferred stock available for designation and issuance. Our board of directors is empowered, without stockholder approval, to issue a series of preferred stock with dividend, liquidation, conversion, voting or other rights which could dilute the interest of, or impair the voting power of, our common stockholders. The issuance of a series of preferred stock could be used as a method of discouraging, delaying or preventing a change in control. For example, it would be possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of our company.
 
We may engage in additional financing that could lead to dilution of existing stockholders.
 
To date, we have financed our activities through revenues from our online sales, the proceeds from sales of our equity securities in private placement financings and the proceeds from the issuance of our promissory notes in private financings.  Any future financings by us may result in substantial dilution of the holdings of existing stockholders and could have a negative impact on the market price of our common stock.  Furthermore, we cannot assure you that such future financings will be possible.
 
We do not anticipate paying dividends in the foreseeable future; you should not buy our stock if you expect dividends.
 
We currently intend to retain our future earnings to support operations and to finance expansion and, therefore, we do not anticipate paying any cash dividends on our common stock in the foreseeable future.


Not applicable.


Our corporate headquarters, which also houses our pharmacy and customer service operations as well as our inventory, is located at 7107 Industrial Road, Florence, Kentucky, 41042. We occupy 62,600 square feet of warehouse space under a lease with a monthly rental rate range from $9,224 to $11,975, however, we recognize rent on a straight line basis in the amount of $9,821.  The lease expires January 1, 2017.  Our leasehold interest is subject to a mechanic's lien in favor of the contractor that assisted with the construction of the facility.  The amount we owed to the contractor was in dispute.  On June 14, 2012, we reached a written settlement with the contractor in which we agreed to pay the contractor the total amount of $189,000, in three equal weekly installments.  We received a general release and release of mechanic's lien from the contractor, which will be effective upon final payment.
 
During 2011, we entered into a one-year lease agreement for an apartment with an entity effective May 31, 2011. The monthly lease rate of $2,850 is in effect for the full term of the agreement.  After the initial term of the lease, the agreement converts to a month to month lease.  Subsequent to December 31, 2012, we renewed this lease through May 31, 2013. 


In the ordinary course of business, we may become subject to lawsuits and other claims and proceedings that might arise from litigation matters or regulatory audits. Such matters are subject to uncertainty and outcomes are often not predictable with assurance. Our management does not presently expect that any such matters will have a material adverse effect on the Company’s consolidated financial condition or consolidated results of operations. We are not currently involved in any pending or threatened material litigation, or other material legal proceedings nor have we been made aware of any penalties from regulatory audits, except as described below.
 
 
 
 

 
 
- 24 -



 

 
On November 29, 2011, NMN Advisors, Inc. filed a complaint against us alleging that we breached a consulting agreement with it.   The complaint seeks damages of $70,000 plus pre-judgment interest.   On February 6, 2012, we filed our answer to the complaint denying that we owe any amounts under the contract, and we also filed a cross-complaint against the plaintiff asserting a number of causes of action, including breach of contract.  Plaintiff filed its answer to our cross-complaint on March 5, 2012.  Both we and the plaintiff have agreed to attempt to resolve the dispute by court mediation. The date for court mediation is tentatively set for July 10, 2012.  If mediation is unsuccessful, we intend to defend against the allegations in the complaint, and pursue the allegations in our cross-complaint, vigorously.

On February 9, 2012, two of our former shareholders, Rock Castle Holdings, LLC and Jason Smith (“Plaintiffs”), filed suit against us in the Hamilton County, Ohio Court of Common Pleas, alleging that we have breached the terms of certain incentive options we granted to them in connection with our now-terminated oral consulting arrangements with them, by among other things, refusing Plaintiffs’ purported exercise of options to purchase 233,332 shares of our common stock at an exercise price of $2.00 per share in December 2011.  Plaintiffs have not specified money damages, but they have requested that, among other things, the court to require us to permit the exercise of the 233,332 options.  We believe the Plaintiffs’ claims are without merit.  On March 13, 2012, the Company moved to dismiss all claims asserted against the Company in the Complaint.  On June 6, 2012, the Court of Common Pleas informed the parties that our motion to dismiss will be denied in its entirety if the Plaintiffs make certain amendments to the Complaint.  The court has given the Plaintiffs until July 6, 2012 to make these amendments, and we expect that the Plaintiffs will make them prior to this deadline.

On March 2, 2012, a former contractor of ours filed suit against us in the Hamilton County, Ohio Court of Common Pleas, alleging that, among other things, we have failed to pay amounts due on certain credit cards that were issued in plaintiff’s name but for which we agreed to assume financial responsibility.  Although we deny any responsibility for the payments owed, we resolved this dispute by entering into a settlement agreement with the plaintiff, and the suit was voluntarily dismissed on May 30, 2012.


Not applicable.

PART II


Market Information

Our shares of common stock are currently quoted on the OTCQB Market Tier under the symbol QB.HEWA.  Our symbol prior to the closing of the Exchange and until August 5, 2009, when we changed it, was IONN.OB.

The following table sets forth the high ask and low bid prices for our common stock for the periods indicated as reported by the OTC BB or OTCQB Market Tier.  On July 16, 2010, we effected a one (1) for twenty (20) reverse split or combination of our Common Stock (the “Reverse Split”).  The Reverse Split became effective for trading purposes on the OTC Market on July 29, 2010. All prices in the following table have been adjusted to reflect the Reverse Split.

 
Quarter
Year ended
December 31, 2011
 
Year ended
December 31, 2010
 
High
Low
High
Low
First
$     6.50
$     3.10
$     3.00
$     1.20
Second
$     6.90
$     4.50
$     4.00
$     2.20
Third
$     5.14
$     2.95
$     4.00
$     2.20
Fourth
$     5.90
$     3.69
$     4.00
$     2.20

 
 

 
 
- 25 -

 
 

 

On May 31, 2012, the closing price of our common stock, as reported by the OTCQB Market Tier, was $7.65 per share.

These bid prices represent prices quoted by broker-dealers on the OTC Market.  The quotations reflect inter-dealer prices, without retail mark-up, mark-down or commissions, and may not represent actual transactions.

As of June 8, 2012, there were 10,244,699 shares of our common stock outstanding.

Holders

As of June 8, 2012, there were approximately 371 holders of record of our common stock.  However, we believe that there are significantly more beneficial holders of our common stock as many beneficial holders hold their stock in “street name.”

Dividends

We have never declared cash dividends on our common stock, nor do we anticipate paying any dividends on our common stock in the future.

Recent Sales of Unregistered Securities

On November 2, 2011, the Company’s Chief Financial Officer, Patrick E. Delaney, exercised options to purchase 31,934 shares of the Company’s common stock in a cashless manner.  On January 6, 2012, Mr. Delaney exercised options to purchase 92,858 shares of the Company’s common stock in a cashless manner.  The options were issued under the Company’s 2009 Incentive Compensation Plan.  The exercise price was $0.80 per share, and the exercises were made under the cashless exercise feature of the Plan.  The sale of the Common Stock was made without registration in reliance on the exemption from registration afforded by Section 4(2) under the Securities Act of 1933 and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering.
 
Subsequent to December 31, 2011, the Company issued an aggregate of 38,891 shares of common stock at a per share price of $4.50 to investors in a private offering. The sale of the Common Stock was made without registration in reliance on the exemption from registration afforded by Section 4(2) under the Securities Act of 1933 and corresponding provisions of state securities laws, which exempt transactions by an issuer not involving any public offering.
 

Not applicable.


Overview
 
We are a VIPPS accredited retail mail-order pharmacy and healthcare e-commerce company that sells discounted generic and brand name prescription drugs, as well as, over-the-counter (OTC) medical products. Our web address is http://www.healthwarehouse.com  and http://www.hocks.com. At present, we sell:
 
·     
a range of prescription drugs (we are licensed as a mail-order pharmacy for sales to 50 states and the District of Columbia);
 
·     
diabetic supplies including glucometers, lancets, syringes and test strips;
 
·     
OTC medications covering a range of conditions from allergy and sinus to pain and fever to smoking cessation aids;
 
 
 

 
 
- 26 -



 
 
 
·     
home medical supplies including incontinence supplies, first aid kits and mobility aids; and
 
·     
diet and nutritional products including supplements, weight loss aids, and vitamins and minerals.
 
Our objectives are to make the pharmaceutical supply chain more efficient and to pass the savings on to the consumer.  We are becoming known by consumers as a convenient, reliable, discount provider of over-the-counter and prescription medications and products. We intend to continue to expand our product line as our business grows. We are presently licensed as a mail-order pharmacy for sales to 50 states and the District of Columbia.  For additional information see Part I Item 1 page 4.
 
Results of Operations
 
The year ended December 31, 2011 compared to the year ended December 31, 2010.
 
   
The year ended
December 31, 2011
   
% of
Revenue
   
The year ended
December 31, 2010
   
% of
Revenue
 
                         
Revenue
  $ 10,363,293       100.0 %   $ 5,691,765       100.0 %
Cost of sales
    5,845,525       56.4 %     3,450,021       60.6 %
Gross profit
    4,517,768       43.6 %     2,241,744       39.4 %
Selling, general & administrative  expenses
    9,246,431       89.2 %     5,303,617       93.2 %
Loss from operations
    (4,728,663 )     (45.6 )%     (3,061,873 )     (53.8 )%
Gain on accounts payable settlement
    32,210       0.3 %     -       - %
Interest income
    4,166       - %     642       - %
Interest expense
    (1,021,112 )     9.9 %     (679,330 )     (11.9 )%
Gain on litigation settlement
    -       - %     48,887       0.9 %
Other income
    1,200       - %     -       - %
Net loss
  $ (5,712,199 )     (55.1 )%   $ (3,691,674 )     (64.9 )%
 
Revenue
 
   
The year ended
December 31, 2011
   
% Change
   
The year ended
December 31, 2010
 
                   
Total revenue
  $ 10,363,293       82.1 %   $ 5,691,765  
 
Net sales for the year ended December 31, 2011 grew to $10,363,293 from $5,691,765 for the year ended December 31, 2010. Revenues increased for the year ended December 31, 2011 compared to the prior year as a result of an increase in order volume in the prescription products sales of $2,889,622, revenues related to the acquisition of Hocks.com in the amount of $2,674,031 and an increase in reimbursed freight revenue of $235,748.  This increase was offset by a decline in the Company’s non Hocks.com over the counter product sales of $607,478 and the decision to leave the business of selling certain prescription products to a manufacturer. The Company expanded into additional and larger markets and increased its focus on business to business activities compared to the prior year. The Company intends to continue this trend towards increasing business to consumer revenues as well as expanding its business to business activities in 2012.

 
Another indicator of increased business activity was that visits to our website increased from 1.5 million in 2010 to over 3.8 million in 2011 an increase of 2.3 million or 153%. Pageviews of our website also increased from 5.2 million in 2010 to over 13.1 million in 2011, an increase of 7.9 million or 152%.
 
 
 

 
- 27 -


 

 
 
Costs and Expenses
 
Cost of Sales and Gross Margin
 
   
The year ended
December 31, 2011
   
%
Change
   
The year ended
December 31, 2010
   
Total cost of sales
  $ 5,845,525       69.4 %   $ 3,450,021  
Total gross profit dollars
  $ 4,517,768       101.5 %   $ 2,241,744  
Total gross margin percentage
    43.6 %     4.2 %     39.4 %

Total cost of sales increased to $5,845,525 for the year ended December 31, 2011 as compared to $3,450,021 for the year ended December 31, 2010 as a result of growth in order volume and revenue. Gross margin percentage increased year-over-year from 39.4% for the year ended December 31, 2010 to 43.6% for the year ended December 31, 2011. The improvement in gross profit margins was due primarily to the shift in product mix to higher margin prescription drugs from approximately 36.1% during the year ended December 31, 2010 to over 47.8% in the year ended December 31, 2011, In addition the Company increased gross margin during 2011 by increasing pricing of over the counter products. These increases in gross margin were offset in part by the Company’s decision to cease selling certain prescription products to manufacturers which had a higher profit margin but limited market growth opportunity. The Company believes that the increase prices for over the counter products as well as the change in product mix with prescription drugs increasing will continue to improve margins during 2012.
 
Selling, General and Administrative Expenses
 
   
The year ended
December 31, 2011
   
%
Change
   
The year ended
December 31, 2010
 
Selling, general and administrative expenses
  $ 9,246,431       74.3 %   $ 5,303,617  
Percentage of revenue
    89.2 %     (3.1 )%     93.2 %
 
Selling, general and administrative expenses increased by $3,942,814 in the year ended December 31, 2011 compared to the same period in 2010, an increase of 74.3%.  The year ended December 31, 2011, expense increases were due primarily to expenses related to the growth in the business, including increased headcount and increases in salary and salary related expenses of $1,478,195, shipping and fulfillment of $1,044,704, advertising expenses of $415,259, merchant credit card fees of $180,626, professional fees of $164,507 and travel related expenses of $131,819. Increases in the following items, not directly related to growth were non-cash stock based compensation expense of $458,158, bad debt of $348,235 and software and engineering of $133,359.  The increases were partially offset by reductions to miscellaneous expenses of $188,541 and contract labor of $103,359.

The increase in payroll related expenses was due to primarily two factors: head count increase from 29 in 2010 to 50 in 2011 and the hiring of certain more highly compensated employees in 2011 compared to 2010. The Company reserved $444,084 in 2011 primarily related to receivables from sales of certain prescription products to manufacturers. The increase in expenses for software engineering compared to 2010 was due primarily to the recognition of non-capitalizable improvements to the web site as reflected in software engineering expenses in 2011. Selling, general and administrative expenses as a percentage of total revenue declined from 93.2% in 2010 to 89.2% in 2011, the Company expects that this percentage decline will accelerate during 2012, due to increased operating efficiencies for head count, rent, and professional fees along with a sharp decline in bad debt expense.
 
 
 
 

 
 
- 28 -


 
 

 
Other income (expense)
 
   
The year ended
December 31, 2011
   
%
Change
   
The year ended
December 31, 2010
 
Gain on accounts payable settlement
  $ 32,210       0 %   $ -  
Interest income
    4,166       548.9 %     642  
Interest expense
    (1,021,112 )     50.3 %     (679,330 )
Gain on litigation settlement
    -       (0 )%     48,887  
Other income (expense)
    1,200       0 %     -  
Total other expense
    983,536       56.2 %     629,801  

Interest expense increased from $679,330 in the year ended December 31, 2010 to $1,021,112 in the year ended December 31, 2011, or an increase of $341,782 or 50.3%. Loan interest expense decreased from $135,279 in December 31, 2010 to $122,927 for the year ended December 31, 2011, or a decrease of $12,352. The non-cash accretion of the debt discount related to our notes and convertible notes payable increased from $543,407 for the year ended December 31, 2010 to $889,185 for the year ended December 31, 2011 or an increase of $345,779. The increase was due primarily to the impact of the Company’s debt financing transactions in September and October 2011.
 
Off-Balance Sheet Arrangements
 
We have not entered into any transactions with unconsolidated entities in which we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.
 
Impact of Inflation
 
We believe that inflation has not had a material impact on our results of operations for the years ended December 31, 2011 and 2010. We cannot assure you that future inflation will not have an adverse impact on our operating results and financial condition.
 
Liquidity and Capital Resources
 
As of December 31, 2011, the Company had negligible cash and a working capital deficiency of $2,404,464.  During the year ended December 31, 2011, the Company generated revenue of $10,363,293 and incurred a net loss of $5,712,199.

Since inception, the Company has financed its operations primarily through product sales to customers, debt and equity financing agreements.  During the year ended December 31, 2011, the Company’s cash decreased by $1,397,543.  Our sources and uses of funds during this period were as follows:

For the year ended December 31, 2011, cash flows included net cash used in operating activities of $2,799,580.  This amount included a decrease in operating cash related to a net loss of $5,712,199 and an increase in accounts receivable $(60,186) due primarily to the sale of prescription products  to our business to business customers and a reduction in accounts payable-related parties of $(218,649) offset by additions for the following items; (i) stock-based compensation expense $948,923 for options issued during 2010 and additional options issued during 2011 (ii) amortization of debt discount $889,186 due primarily to the debt discount impact of the Company’s debt financing transactions in September and October 2011 (iii) Accounts payable – trade $508,107 (iv) Provision for doubtful accounts for $444,084(v) depreciation and amortization, $248,398 (vi) accrued expenses, $98,904. For the year ended December 31, 2010, cash flows included net cash used in operating activities of $2,483,166.  This amount included a decrease in operating cash related to a net loss of $3,691,674 and an increase in accounts receivable $(507,707) due primarily to the sale of prescription products to manufacturers offset by additions for the following items; (i) amortization of debt discount, $543,407 due primarily to the debt discount related to warrants issued for two short term notes (ii) stock-based compensation expense, $490,765 for options issued during 2009, 2010 and additional options issued during 2011 (iii) depreciation and amortization, $198,836 (iv) accounts payable-related parties, $159,604 the increase was related to improved payment terms (iv) accrued expenses, $98,098 the majority of which was related to the November 8, 2010 financing.
 
 
 
 

 
- 29 -



 
 
For the year ended December 31, 2011, net cash used in investing activities was $883,868. This was primarily due to the acquisition of equipment and leasehold improvements of $452,322 and the $200,000 cash portion of the Hocks.com acquisition. For the year ended December 31, 2010, net cash used in investing activities was $151,600 primarily due to the acquisition of equipment and leasehold improvements.

For the year ended December 31, 2011, net cash provided by financing activities was $2,285,905. Cash was provided by the sale of 597,542 shares of the Company’s common stock for cash proceeds of $1,972,241, two notes payable for an aggregate amount of $3,000,000,  $1,000,000 provided by the sale of 10,000 shares of the Company’s redeemable preferred series C stock, and advances from a stockholder in the amount of $300,000. These amounts were offset in part by the use of $3,419,715 cash to repurchase 1,179,212 shares of the Company’s common stock from Rock Castle Holdings, Inc., and repayment of $1,000,000 of notes payable.  For the year ended December 31, 2010, net cash provided by financing activities was $3,841,168, consisting of a sale of preferred stock of $3,205,168 net of expenses paid in conjunction with the sale of approximately $145,012 and the sale of convertible notes of $150,000.
 
Management believes that the Company has taken certain steps to improve its operations and cash flows, including improved inventory management and an increase in the number of suppliers. The acquisition of Hocks.com is also expected to improve the operating productivity and efficiency of the Company’s expenditures for selling, general and administrative activities. Further the Company has taken additional steps to increase the profitability derived from the acquisition of Hocks.com including significantly increasing the gross margin while decreasing the amounts spent on rent and payroll related expenses. Management believes that this plan will be successful, but there can be no such assurance.
 
Subsequent to December 31, 2011, the Company received advances from certain shareholders aggregating $545,000 (of which $205,000 has been repaid as of the date of this report) and the repayment of employee advances aggregating $235,000. In addition, the Company received proceeds from the sale of common stock in the amount of $175,010 and from the exercise of stock options in the amount of $26,662.  Management believes the Company needs to raise additional capital in order to meet operations and execute its business plan.  However, there is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company and whether the Company will be able to turn into a profitable position and generate positive operating cash flow. If the Company is unable to raise sufficient additional funds, it will have to develop and implement a plan to extend payables and reduce overhead until sufficient additional capital is raised to support further operations. There can be no assurance that such a plan will be successful.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Notwithstanding the foregoing, the accompanying consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the company as a going concern and the realization of assets and the satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the financial statements do not necessarily purport to represent realizable or settlement values. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Critical Accounting Policies and Estimates
 
Use of Estimates

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.  The Company’s significant estimates include reserves related to accounts receivable and inventory, the recoverability and useful lives of long-lived assets, the valuation allowance related to deferred tax assets, the valuation of equity instruments and debt discounts, and the valuation of assets acquired in connection with Hocks Acquisition Corporation’s (“Hocks Acquisition”) February 14, 2011 purchase of the business and assets of Hocks Pharmacy Inc. (“Hocks Pharmacy”).
 
On an ongoing basis, we evaluate our estimates and judgments. We base our estimates and judgments on a variety of factors including our historical experience, knowledge of our business and industry, current and expected economic conditions, the composition of our products/services and the regulatory environment.  We periodically re-evaluate our estimates and assumptions with respect to these judgments and modify our approach when circumstances indicate that modifications are necessary.
 
 
 

 
 
- 30 -



 
 
While we believe that the factors we evaluate provide us with a meaningful basis for establishing and applying sound accounting policies, we cannot guarantee that the results will always be accurate.   Since the determination of these estimates requires the exercise of judgment, actual results could differ from such estimates.
 
Stock Compensation
 
Stock-based compensation expense for all stock-based payment awards is based on the estimated grant-date fair value. The Company recognizes these compensation costs over the requisite service period of the award, which is generally the option vesting term.  Option valuation models require the input of highly subjective assumptions including the expected life of the option. During the year ended December 31, 2010 and prior periods, the fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data existed to estimate the volatility using the Company’s own historical stock prices.  During the year ended December 31, 2011, the Company began to use the historical trading prices of its own common stock as a component in the calculation of an estimated volatility figure to determine the fair value of stock-based payment awards using the Black-Scholes model. Management determined this assumption to be a better indicator of value. The Company accounts for the expected life of options in accordance with the “simplified” method which enables the use of the simplified method for “plain vanilla” share options as defined in Staff Accounting Bulletin No. 107. 

Recently-issued Accounting Pronouncements
 
The information contained in Footnote 14 to the Company’s consolidated financial statements included in Item 8 to this annual report is incorporated herewith by reference.


Not applicable.


The financial statements required hereby are located on pages 55 through 78.


None.
 
 
Evaluation of Disclosure Controls and Procedures
 
Disclosure controls and procedures (as defined in Rules 13a-15 (e) and 15d–15(e) under the Exchange Act) are designed to provide reasonable assurance that information required to be disclosed in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the forms and rules of the SEC and that such information is accumulated and communicated to management, including the CEO and CFO, in a manner to allow timely decisions regarding required disclosures.
 
In connection with the preparation of this Form 10–K, our management, including the CEO and CFO, evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of December 31, 2011. As described below, management has identified material weaknesses in our internal control over financial reporting, which is an integral component of our disclosure controls and procedures. As a result of those material weaknesses, our management has concluded that, as of December 31, 2011 our disclosure controls and procedures were not effective.
 
 
 

 
 
- 31 -


 
 
 
Management’s Report on Internal Control over Financial Reporting
 
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined In Exchange Act Rule 13a-15(f).  The term “internal control over financial reporting” is defined as a process designed by, or under the supervision of, the registrant’s principal executive and principal financial officers, or persons performing similar functions, and effected by the registrant’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:
 
·     
pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the registrant;
 
·     
provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the registrant are being made only in accordance with authorizations of management and directors of the registrant; and
 
·     
provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the registrant’s assets that could have a material effect on the financial statements.
 
Our internal control system is designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs.  In addition, because of changes in conditions, the effectiveness of internal control may vary over time.
 
Management conducted an evaluation of the effectiveness of the Company’s internal control over financial reporting based on the criteria in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) and identified the material weaknesses described below. In conducting this evaluation, management took into account the information identified and conclusions reached by the non-management directors in the Review.  Based on this evaluation and upon consideration of the material weaknesses it identified, management concluded that the Company’s internal control over financial reporting was not effective as of December 31, 2011. A “material weakness” is a significant deficiency, or combination of significant deficiencies, that results in more than a remote likelihood that a material misstatement of our annual or interim financial statements will not be prevented or detected by our employees.
 
The specific material weaknesses that management identified in our internal controls as of December 31, 2011 are as follows:
 
·     
We did not develop appropriate accounting policies and procedures, including the review and supervision, for all necessary areas and did not effectively communicate our existing policies to our employees.
 
·     
We did not have a sufficient number of adequately trained technical accounting and external reporting personnel to support standalone external financial reporting under OTCQB or SEC requirements.
 
·     
We did not have personnel with sufficient experience with United States generally accepted accounting principles to address complex transactions.
 
·     
We did not have effective controls over disbursements to assure that disbursements were properly authorized and recorded or that our existing controls could not be circumvented.
 
·     
We did not maintain a fully integrated financial consolidation and reporting system throughout the year and as a result, extensive manual analysis, reconciliation and adjustments were required in order to produce financial statements for external reporting purposes.
 
 
 
 

 
 
- 32 -


 

 
 
·     
We did not appropriately segregate employees’ duties in connection with the review and approval of certain transactions, reconciliations and other processes in day-to-day operations.
 
·     
We did not have effective policies and procedures to ensure that senior management and the Board of Directors would receive timely information about, and be able to identify, evaluate and approve, related party transactions.
 
See "Recent Developments" for a description of certain matters related to these control deficiencies.
 
Plans For Remediation of Material Weaknesses

We are in the process of implementing changes to strengthen our internal controls.  We are in the process of developing a remediation plan for the identified material weaknesses and we expect that work on the plan will continue throughout 2012.  Specifically, to address the material weaknesses arising from insufficient accounting personnel, the Company removed one member of the accounting staff who was determined not to have sufficient accounting expertise, and the Company plans to (i) hire a full-time Chief Financial Officer who will be on-site throughout the year and (ii) hire two additional full-time accounting personnel during 2012.  To address the material weakness arising from inadequate control over disbursements, the Company has canceled certain credit cards, limited the number of personnel with authority over the Company's bank accounts and is in the process of revising its policies and procedures for review and approval of employee disbursements and expenses.  The Company is currently evaluating what additional policies and procedures may be necessary, how to most effectively communicate the policies and procedures to its personnel and how to improve the integration of its financial consolidation and reporting system.  Where appropriate, the Company is receiving advice and assistance from the third-party experts as it implements and refines its remediation plan.
 
Additional measures may be necessary, and the measures we expect to take to improve our internal controls may not be sufficient to address the issues identified, to ensure that our internal controls are effective or to ensure that such material weakness or other material weaknesses would not result in a material misstatement of our annual or interim financial statements. In addition, other material weaknesses or significant deficiencies may be identified in the future. If we are unable to correct deficiencies in internal controls in a timely manner, our ability to record, process, summarize and report financial information accurately and within the time periods specified in the rules and forms of the SEC will be adversely affected. This failure could negatively affect the market price and trading liquidity of our common stock, cause investors to lose confidence in our reported financial information, subject us to civil and criminal investigations and penalties, and generally materially and adversely impact our business and financial condition.
 
           Changes in Internal Control Over Financial Reporting
 
           There were no changes in our internal control over financial reporting or in other factors during the quarter ended December 31, 2011, that have materially affected, or were reasonably likely to materially affect, our internal control over financial reporting. The Company believes that the implementation of plans for remediation of material weaknesses, referenced in the above section, will have additional benefits of improving internal controls over financial reporting. The Company is a non-accelerated filer and is not subject to Section 404(b) of the Sarbanes Oxley Act. Subsequent to December 31, 2011, the Company hired temporary personnel and a consulting group to assist with its financial reporting process.
 

None.

PART III


Executive Officers and Directors

The names, ages and positions of our executive officers and directors as of May 31, 2012 are as follows:
 
 
 
 

 
- 33 -


 
 

 
Name
 
Age
 
Position
         
Lalit Dhadphale
 
40
 
President, Chief Executive Officer and
Director
Patrick E. Delaney
 
59
 
Chief Financial Officer, Treasurer
and Secretary
Youssef Bennani
 
45
 
Director
Matthew Stecker
 
43
 
Director
Joseph Savarino
 
42
 
Director
John Backus
 
53
 
Director

The principal occupations for the past five years (and, in some instances, for prior years) of each of our executive officers and directors are as follows:

Lalit Dhadphale co-founded HealthWarehouse.com in August 2007 and launched the company's prescription drug business in 2008. He has been President and CEO of the company since its inception and has served as Chairman of the Board of Directors since May 2009. The Company has grown from a start-up business to publicly traded on the OTC Bulletin Board (Ticker: HEWA), servicing 250,000 customers and shipping more than 150,000 prescriptions in 2011.  The Company has acquired 50 state licenses to sell prescription medications and is 1 of only 27 VIPPS (Verified Internet Pharmacy Practice Sites) accredited pharmacies in the U.S.  HealthWarehouse.com is also a 2009, 2010 and 2011 winner of the BizRate Circle of Excellence Award for outstanding customer service and satisfaction. Earlier in his career, Lalit founded Zengine, Inc. serving as Vice President of Product Development, Chief International Officer and later as Chief Operating Officer of Zengine, Inc. from founding in 1999 through its sale in 2002. Under his day-to-day leadership, Zengine grew from start-up to $30+ million in annualized sales, achieving profitability in its second quarter as a public company in the first quarter of 2001.  Prior to co-founding Zengine, Mr. Dhadphale was a co-founder of Excite Japan, where he was involved with product development, internationalization and localization of web sites and Internet products. He produced the launch of both Excite Japan and Netscape Netcenter Japan. Prior thereto, Mr. Dhadphale was International Business Development Manager for CNET, securing relationships throughout Asia and the Pacific Rim. Mr. Dhadphale received his BA degree from the University of Michigan, Ann Arbor in Japanese Language & Literature and Asian Studies.

Patrick E. Delaney became our Chief Financial Officer, Treasurer and Secretary on May 14, 2009, and served as the Chief Financial Officer of Clacendix from September 2003 to the merger date.  Prior to joining our company, from 2000 until 2003, Mr. Delaney was the President of Taracon, Inc. a privately owned independent consulting firm that provides management consulting for early and mid-stage technology and financial services companies. Mr. Delaney also served as Chief Financial Officer for two publicly traded telecommunications providers, Pointe Communications Corporation from 1993 to 2000 and Advanced Telecommunications Corporation from 1986 to 1993. Mr. Delaney has served other companies in executive capacities including RealCom Communications, Argo Communications and ACF Industries.
 
Youssef Bennani became a member of our Board of Directors on November 11, 2009.  Through January 30, 2012, Mr. Bennani was a Senior Managing Director in Kaufman Bros., L.P.’s Investment Banking department which he joined in 1995.  His responsibilities range from public and private financing transactions to general financial advisory for mergers and acquisition, restructuring, acquisition financing and recapitalization.  Prior to joining Kaufman Bros., L.P., Mr. Bennani was an investment banker at Barington Capital, L.P., where primary industry focus was technology. Mr. Bennani received his MBA in international finance from New York University’s Stern School of Business. He also received his Masters in computer science as well as a BS in mathematics and physics from the University of Pierre and Marie Curie in Paris.  In addition to the international and investment banking experiences, Mr. Bennani brings a depth of knowledge of finance that permits him to qualify as the “financial expert” on the Board of Directors.
 
 
 
 
 

 
- 34 -


 

 
Matthew Stecker became a member of our board of directors on December 8, 2010. Since 2009 through present, Mr. Stecker is the CEO and President of Livewire Mobile, a leading provider of managed personalization services for mobile operators. From 2005-2009, Mr. Stecker was Principal and Vice President of The Management Network Group. Under the Certificate of Designation designating the rights and privileges of the Company’s Series B Preferred Stock, the holders of the Company’s Series B Preferred Stock have the right to designate or elect one of the Company’s directors (the “Series B Director”).  The holders of a majority of the Company’s outstanding Series B Preferred shares have designated Mr. Stecker as the initial Series B Director.

Joseph Savarino became a member of our board of directors on December 22, 2010.  Since June 2010, Mr. Savarino is a partner of Carpeturn.com, Inc. which provides flooring materials and services to the multi-family housing industry.  Mr. Savarino was engaged in select internet consulting projects during 2002 through June 2010, and has prior experience in sales, business development and market research positions. Mr. Savarino was the President and Chief Executive Officer of Zengine Inc., a public company that was a sell-side e-business software and service provider, from 1998 until its sale in 2002.

John Backus became a member of our Board of Directors on August 2, 2011. Mr. Backus is the founder and managing partner of New Atlantic Ventures, an early stage information technology venture capital fund.  Mr. Backus is a seasoned technology investor and entrepreneur with 25+ years of experience investing in and managing rapidly growing, high-technology companies.  Prior to founding New Atlantic Ventures in 1998, Mr. Backus was a founding investor and the President and Chief Executive Officer of InteliData Technologies, a Fast 50 growth company in both 1997 and 1998.  Mr. Backus led InteliData’s predecessor, US Order, through a successful $65 million IPO in 1995.  Mr. Backus currently manages a $225 million venture portfolio at New Atlantic Ventures.  On August 2, 2011, New Atlantic Venture Fund III, L.P., and certain affiliated entities (“NAV”), purchased from the Company an aggregate of 428,572 shares of the Company’s Common Stock in a directly negotiated transaction.  As part of this transaction, NAV is entitled to have, so long as it owns in the aggregate, at least ten percent (10%) of the Company’s outstanding Common Stock, a designated representative appointed to the Company’s Board of Directors.  NAV designated Mr. Backus as its initial Board representative. In addition to HealthWarehouse.com, he currently serves on the board of directors of AppTap, Invincea, Koofers, My Wines Direct, & Qliance. He is the past Chairman of the Wolf Trap Foundation Board of Directors, the past Chairman of the Northern Virginia Technology Council (NVTC) Board of Directors, the founding Chairman and current Board member of the NVTC TechPAC, and was appointed by former Virginia Governor Mark Warner to co-chair the Virginia Research and Technology Advisory Commission which he served on for 4 years.   John began his career at Bain & Co. and Bain Capital, where he was the first Bain & Co. management consultant to take a full time operating role (as CFO) in a portfolio company.

All directors hold office until the next annual meeting of stockholders and the election and qualification of their successors.  Officers are appointed annually by the board of directors and serve at the discretion of the board.

Committees of the Board of Directors

Our board of directors had previously established an audit committee and a compensation committee, and a nominating committee. In conjunction with the Exchange, we disbanded these committees. On April 8, 2010, our board of directors by written consent recreated an audit committee and during 2012 the Board expects to recreate a compensation committee, in compliance with established corporate governance requirements.

Audit Committee

The Company established an audit committee of the board of directors. The audit committee’s duties are to recommend to the board of directors the engagement of independent registered public accountants to audit our financial statements and to review our accounting and auditing principles. The audit committee will review the scope, timing and fees for the annual audit and the results of audits performed by the independent registered public accountants, including their recommendations to improve the system of accounting and internal controls. The audit committee will at all times be composed exclusively of directors who are, in the opinion of the board of directors, free from any relationship which would interfere with the exercise of independent judgment as a committee member and who possess an understanding of financial statements and generally accepted accounting principles. Mr. Youssef Bennani serves as the “audit committee financial expert,” as defined under securities laws.
 
 
 

 
 
- 35 -


 
 

 
Compensation Committee

We plan to reestablish a compensation committee of the board of directors. The compensation committee would review and approve our salary and benefits policies, including compensation of executive officers.  The compensation committee would also administer our 2009 Incentive Compensation Plan, and recommend and approve grants of stock options and restricted stock under that plan. The compensation committee was formed on April 16, 2012.

Nominating Committee

We do not plan to reestablish a standing nominating committee. Nominations for election to our board of directors may be made by the board of directors or by any stockholder entitled to vote for the election of directors in accordance with our bylaws and Delaware law.

Board Operation and Leadership Structure

The Board has adopted Corporate Governance Principles which along with the Charters for its Committees and the Company Code of Business Conduct and Ethics, provides a framework for the governance of the Company. The Company’s Corporate Governance Principles address matters such as the responsibilities and composition of the Board, Director Independence and the conduct of Board and Committee meetings.  The Company’s Code of Business Conduct and Ethics sets forth guiding principles of business ethics and certain legal requirements applicable to all Company employees and Directors.

Currently, the Company’s Chief Executive Officer also holds the position of Chairman of the Board of Directors.  In the future, however, the Board may reconsider whether its Chief Executive Officer should also serve as Board Chairman.

Code of Ethics

We have adopted a code of ethics that applies to all of our employees, including our principal executive officer, principal financial officer, and principal accounting officer or controller. A copy of the Company's code of ethics will be provided free of charge, upon written request to 7107 Industrial Road, Florence, KY, 41042, and our telephone number is (513) 618-0913.

Indebtedness of Directors and Executive Officers

None of our executive officers or directors, or their respective associates or affiliates, is indebted to us.

Legal Proceedings

As of June 8, 2012, there were no material proceedings to which any of our directors, executive officers, affiliates or stockholders is a party adverse to us.

Family Relationships

There are no family relationships among our executive officers and directors.

Compliance with Section 16(a) of the Exchange Act

Rock Castle Holdings, LLC, which was a more than 10% stockholder of the Company during portions of 2011, failed to file six Form 4s on a timely basis, reporting in the aggregate 14 transactions during 2011 in which it sold shares of the Company’s Common Stock in the open market.
 
 
 

 
 
- 36 -


 
 

 
New Atlantic Venture Fund III, L.P. and its affiliates, a more than 10% stockholder of the Company, failed to file one Form 4 on a timely basis reporting its acquisition during 2011 of warrants to purchase shares of the Company’s Common Stock.

Cape Bear Partners, LLC, a more than 10% stockholder of the Company, failed to file one Form 4 on a timely basis reporting its acquisition during 2011 of warrants to purchase shares of the Company’s Common Stock.

Lalit Dhadphale, the Company’s President and Chief Financial Officer, failed to file one Form 4 on a timely basis reporting his acquisition during 2011 of options to purchase shares of the Company’s Common Stock.

Joseph Savarino, a director of the Company, failed to file one Form 4 on a timely basis reporting his purchase during 2011 of shares of the Company’s Common Stock from the Company in a private, directly negotiated transaction.

Stockholder Recommendations of Board Nominees

There have been no material changes to the procedures by which our stockholders may recommend nominees to our board of directors since out last proxy statement filed with the SEC.


The table below summarizes the compensation earned for services rendered to the Company, in all capacities, for the years indicated, by its Chief Executive Officer and three most highly-compensated officers or employees other than the Chief Executive Officer.

Summary Compensation Table

 
Name and
Principal Position
 
 
Year
 
Salary
($)
 
Bonus
($)
 
Option Awards
($) (1)
All Other
Compensation
($)
 
Total
($)
             
Lalit Dhadphale
President and Chief Executive Officer
2011
2010
250,000
92,434
83,750
142,606
891,569(1)
323,726 (1)
0
0
1,225,319
558,766
             
Patrick E. Delaney
Chief Financial
Officer, Treasurer
and Secretary
2011
2010
 
84,000
81,625
 
 
0
 
 
0 (1)
 
1,948 (2)
1,948 (2)
 
85,948
83,573
 
             
Eric Lambert
Pharmacist
2011
212,445
 
 
189,067 (1)
 
0
 
401,512
             
Kip Ferguson
Pharmacist
2011
2010
120,000
121,538
0
0
0
      0 (1)
 
0
0
120,000
121,538

(1)           The amounts in the “Option Awards” column reflect the dollar aggregate grant date fair value computed in accordance with ASC Topic 718. The assumptions we used to calculate these amounts are discussed in the notes to our consolidated financial statements included in this report on Form 10-K.

(2)           Includes life insurance and disability insurance premiums paid by Company for executives.
 
 
 

 
 
- 37 -



 
 
Narrative Disclosure to the Summary Compensation Table

In connection with the closing of the Exchange, effective May 15, 2009, we adjusted Mr. Delaney’s compensation to an annualized base salary of $84,000. Mr. Delaney remains eligible to receive reimbursement for medical benefits and life and disability insurance, as well as reimbursement for reasonable business expenses.

On October 14, 2010, we awarded Mr. Dhadphale an incentive stock option to purchase 250,000 shares of Common Stock at $3.03 per share, all of which have a five year term.  These options vest in equal annual installments on October 14, 2011, October 14, 2012, and October 14, 2013.

On October 14, 2010, we increased the annual base salary of Mr. Dhadphale to $250,000 effective October 1, 2010, and granted Mr. Dhadphale a discretionary bonus of $86,000, to be paid in 12 equal monthly installments.

On August 31, 2011, we awarded Mr. Dhadphale an incentive stock option to purchase 250,000 shares of Common Stock at $3.80 per share, all of which have a five year term.  These options vest on the date Mr. Dhadphale personally, by means of a pledge of common stock, secures a pending economic development loan to the Company from the Commonwealth of Kentucky.

On November 7, 2011, we granted Mr. Dhadphale a discretionary bonus of $86,000, to be paid in 12 equal monthly installments.

On February 11, 2011, we awarded Mr. Lambert an incentive stock option to purchase 25,000 shares of Common Stock at $4.10 per share, all of which have a ten year term.  The options vest in equal installments on February 11, 2012, February 11, 2013 and February 11, 2014.

On July 13, 2011, we awarded Mr. Lambert an incentive stock option to purchase 30,000 of Common Stock at $4.62 per share, all of which have a ten year term.  The options vest in equal installments on July 13, 2012, July 13, 2013 and July 13, 2014.

Outstanding Equity Awards at Fiscal Year End

The following table summarizes equity awards outstanding at December 31, 2011, for each of the executive officers named in the Summary Compensation Table above:

 
 
OUTSTANDING EQUITY AWARDS AT 2011 FISCAL
Name
Number
of
Securities
Underlying
 Unexercised
Options
(#)
Exercisable
Number of
Securities
Underlying
Unexercised
Options
(#)
Unexercisable
Equity Incentive
Plan Awards:
Number of
Securities
Underlying
Unexercised
Unearned
Options
(#)
Option
Exercise
Price
($)
Option
Expiration
Date
           
Lalit Dhadphale
Chief Executive Officer and President
166,666(1)
83,333(2)
--
83,334(1)
166,667(2)
250,000(3)
--
2.20
3.03
3.80
5/20/14
10/14/15
8/31/16
           
Patrick E. Delaney
Chief Financial Officer and Treasurer
105,450(4)
8,787 (5)
66,666(6)
--
8,788(5)
33,334(6)
--
0.80
0.80
2.50
5/15/14
5/15/19
11/11/19
           
Eric Lambert
Pharmacist
-------
25,000 (7)
30,000 (8)
--
4.10
4.62
2/11/21
7/13/21

 
 
 

 
 
- 38 -


 
 

 
(1)           Options vested 33⅓% on each of May 20, 2010 and May 20, 2011, then vest 33⅓% on May 20, 2012.

(2)           Options vested 33⅓% on October 14, 2011, and then vest 33⅓% on each of October 14, 2012 and October 14, 2013.

(3)           Options vest on the effective date Mr. Dhadphale personally provides certain credit support for a pending economic development loan to the Company from the Commonwealth of Kentucky.

(4)           All options were fully vested as of the grant date.

(5)           Options vested 33⅓% on May 15, 2010, and then vested 8⅓% on the last day of each calendar quarter beginning June 30, 2010.

(6)           Options vested 33⅓% on each of November 11, 2010 and November 11, 2011, and then vest 33⅓% on November 11, 2012.

(7)           Options vest 33⅓% on each of February 11, 2012, February 11, 2013 and February 11, 2014.

(8)           Options vest 33⅓% on each of July 13, 2012, July 13, 2013 and July 13, 2014.

Employment Agreements

None of our employees are subject to employment agreements with us. We intend to enter into an employment agreement with Lalit Dhadphale, our President and Chief Executive Officer, in the near future.

Severance and Change in Control Arrangements

We do not have any agreements or arrangements providing for payments to any of our officers and directors in the event of a change in control or termination.

Director Compensation

We expect to compensate non-management directors primarily through stock option or restricted stock grants under our stock option plans.  At this time, we grant non-management directors options to purchase 30,000 shares upon their initial election to the board, and options to purchase 15,000 shares on an annual basis for serving on the board.  Directors are expected to timely and fully participate in all regular and special board meetings, and all meetings of committees that they may serve on.

The table below summarizes the compensation we paid to non-management directors for the fiscal year ended December 31, 2011

2011 DIRECTOR COMPENSATION

Name
Option Awards
($) (5)
   
Total ($)
 
                 
Joseph Savarino (1)
    66,555       66,555  
Norman E. Corn (2)
    33,277       33,277  
Youssef Bennani (3)
    33,277       33,277  
John C. Backus (4)
    95,401       95,401  

(1)           Mr. Savarino was elected to our Board effective December 22, 2010.  In connection with his election, on February 11, 2011 we granted Mr. Savarino options to purchase 30,000 shares of our Common Stock, at an exercise price of $4.10 per share, and with a term of ten years.  The options vest 33⅓% on each of February 11, 2012, February 11, 2013 and February 11, 2014.
 
 
 

 
 
- 39 -


 
 
 

 
(2)           In connection with his annual service on our Board, on February 11, 2011 we granted Mr. Corn options to purchase 15,000 shares of our Common Stock, at an exercise price of $4.10 per share, and with a term of ten years.  The options originally vested 33⅓% on each of February 11, 2012, February 11, 2013 and February 11, 2014.  Mr. Corn resigned from our Board effective August 1, 2011.  In connection with his resignation, our Board accelerated the vesting of these options so that they became 100% exercisable on August 2, 2011.

(3)           In connection with his annual service on our Board, on February 11, 2011 we granted Mr. Bennani options to purchase 15,000 shares of our Common Stock, at an exercise price of $4.10 per share, and with a term of ten years.  The options vest 33⅓% on each of February 11, 2012, February 11, 2013 and February 11, 2014.

(4)           Mr. Backus was elected to our Board effective August 2, 2011.  In connection with his election, on August 12, 2011 we granted Mr. Backus options to purchase 30,000 shares of our Common Stock, at an exercise price of $3.30 per share, and with a term of ten years.  The options vest 33⅓% on each of August 12, 2012, August 12, 2013 and August 12, 2014.

(5)           The amounts in the “Option Awards” column reflect the dollar aggregate grant date fair value computed in accordance with ASC Topic 718.


Equity Compensation Plan Information

On May 15, 2009, we adopted our 2009 Incentive Compensation Plan (the 2009 Plan). The total number of shares of Common Stock that may be subject to the granting of awards under the 2009 Plan (as amended) is 2,700,000, plus 181,425 shares that remained available on May 15, 2009 under our 2006 Stock Option Plan.  The 2009 Plan imposes individual limitations on the amount of certain awards. Under these limitations, during any fiscal year of our Company, the number of options, stock appreciation rights, shares of restricted stock, shares of deferred stock, performance shares and other stock based-awards granted to any one participant under the 2009 Plan may not exceed 250,000 shares, subject to adjustment in certain circumstances. The maximum amount that may be paid out as performance units in any 12-month performance period is $2,000,000, and the maximum amount that may be paid out as performance units in any performance period greater than 12 months is $4,000,000. The maximum term of each option or stock appreciation right, the times at which each option or stock appreciation right will be exercisable, and provisions requiring forfeiture of unexercised options or stock appreciation rights at or following termination of employment generally are fixed by the Board, except that no option or stock appreciation right may have a term exceeding ten years. The exercise price per share subject to an option and the grant price of a stock appreciation rights are determined by the Board, but in the case of an incentive stock option (ISO) must not be less than the fair market value of a share of Common Stock on the date of grant. As of December 31, 2011, stock options to purchase up to 2,165,925 shares of Common Stock have been awarded under the 2009 Plan, with exercise prices ranging from $0.80 to $4.62 per share, of which approximately 870,644 are exercisable. All of these options have a five or ten year term.

 
 
 
 

 
 
- 40 -


 
 

 
Securities Authorized for Issuance Under Equity Compensation Plans
 
The following table provides information as of December 31, 2011, with respect to the shares of common stock that may be issued under our existing equity compensation plan.
 
Equity Compensation Plan Information

Plan category
Number of shares of
common stock to be
issued upon exercise
of outstanding options, warrants
and rights
(a)
Weighted-average
exercise price of
outstanding options,
warrants and rights
(b)
Number of securities
remaining available
for future issuance
under equity
compensation plans
(excluding securities
reflected in column
(a)) (c)

Equity compensation
plans approved
by security holders
 
2,165,925 (1)
$2.89
633,566 (2)

Equity compensation
plans not approved by
security holders (3)
 
2,916,590
$2.67
 
-0-
Total
5,082,515
$2.76
633,566
 
(1)         Consists of options to purchase 2,165,925 shares of our Common Stock granted under our 2009 Incentive Compensation Plan (the “2009 Plan”), with exercise prices ranging from $0.80 to $4.62 per share.
 
(2)         Remaining shares available as of December 31, 2011 for future issuance under our 2009 Plan (including 181,425 shares that remained available on May 15, 2009 under our 2006 Plan and that are now available for issuance under our 2009 Plan)
 
(3)          Description of equity compensation plans not approved by security holders:
 
On December 15, 2009, we entered into a Loan and Security Agreement (the “Loan Agreement”) with HWH Lending LLC, a Delaware limited liability company (“HWH”).  Under the terms of the Loan Agreement, we borrowed $515,000 from HWH on December 15, 2009, and we borrowed an additional $500,000 from HWH on May 3, 2010 (together, the “Loans”). The proceeds of the Loans were used by us for working capital purposes.  The Loans bore interest at the rate of 12% per annum, payable at maturity.  The maturity date of each Loan was one year from the date of the Loan.  The Loans were repaid by us in connection with the 2010 Private Placement described below.  In consideration of the Loans, we granted HWH warrants to purchase 625,000 shares of our Common Stock at a purchase price of $1.60 per share.  Each warrant may be exercised in whole or in part and from time to time for a term of five years from its grant date.  The warrants contain anti-dilution and purchase price adjustment provisions in the event of reorganization, consolidation or merger, certain dividends, stock split or reverse stock split..  The warrants are transferable in whole or in part, so long as the transfers comply with applicable securities laws.  In November 2010, HWH transferred warrants to purchase 312,500 shares of our Common Stock to Milfam I., L.P., a Georgia limited partnership.
 
On November 8, 2010, we entered into a Securities Purchase Agreement (the “Purchase Agreement”, with four accredited investors (the “Investors”) and sold certain securities to the Investors in a non-public offering under Section 4(2) and under Rule 506 of Regulation D under the Securities Act of 1933 (the “2010 Private Placement”).  Under the terms of the Purchase Agreement, we sold a total of 365,265 newly authorized shares of $0.001 par value Series B preferred stock (the “Series B Preferred Stock”) to the Investors at $9.45 per share, for an aggregate price of approximately $3,450,000.  Each share of the Series B Preferred Stock may be converted at any time, in whole or in part, into five shares of our Common Stock, as adjusted.  We also entered into a separate Loan and Security Agreement dated November 8, 2010 with two of the Investors (the “2010 Loan Agreement”).  Under the terms of the 2010 Loan Agreement and the Purchase Agreement, we sold convertible promissory notes to those Investors in the aggregate principal amount of $1,000,000 (the “Convertible Notes”). The Convertible Notes bear interest at the rate of 7% per annum compounded annually.  The principal amount and all accrued interest on the Convertible Notes are payable on December 31, 2012, or earlier on an event of default or a sale or liquidation of the Company.  The principal amount and accrued interest on the Convertible Notes may be converted at any time into shares of Series B Preferred Stock at a conversion price of $9.45 per share, as adjusted. We used the net proceeds from the 2010 Private Placement to expand our online presence, upgrade our technology infrastructure, and pay existing indebtedness and accrued expenses, and for general working capital purposes.  Under the terms of the Purchase Agreement, we also issued warrants to the Investors, prorata to their investment amounts, to purchase an aggregate of 1,271,590 shares of our Common Stock at an exercise price of $3.00 per share.  Each warrant may be exercised in whole or in part and from time to time for a term of five years from its grant date.  The warrants are transferable in whole or in part, so long as the transfers comply with applicable securities laws.
 
 
 
 

 
- 41 -


 
 

 
In connection with the relocation of our facilities to the Commonwealth of Kentucky (the “State”), we are eligible to receive various economic incentives from the State, including an economic development loan of $500,000 (the “Development Loan”), which we may become obligated to repay in whole or in part over the next three years depending on certain criteria such as the level of hiring of additional employees.  In order to make the Development Loan, the State is requiring that the repayment of the Development Loan be secured by various types of collateral.  Cape Bear Partners, LLC, a more than 10% stockholder of the Company, has agreed to personally provide certain credit support for the Company’s obligations under the Development Loan, including a pledge of shares of Company Common Stock (the “Pledge”).  In consideration of the Pledge, on August 31, 2011, we issued to Cape Bear a warrant to purchase 250,000 shares of our Common Stock at an exercise price of $2.90 per share.  The warrant will become vested and exercisable on the effective date of the Pledge, and is for a term of ten years from the grant date.

On September 2, 2011, we entered into a Loan and Security Agreement (the “2011 Loan Agreement”) with the same two lenders as under the 2010 Loan Agreement (the “Lenders”).  Under the terms of the 2011 Loan Agreement, we borrowed $1,500,000 from each Lender for a total of $3,000,000 (the “2011 Loans”).  The 2011 Loans are evidenced by non-convertible, secured promissory notes, bearing interest at 7% per annum, payable at maturity.  The principal amount and all accrued interest on the 2011 Loans are payable on January 15, 2013, or earlier on an event of default or a sale or liquidation of the Company.  In connection with 2011 Loans, we also granted each Lender a warrant to purchase 250,000 shares of our Common Stock at a purchase price of $2.90 per share.  Each warrant may be exercised in whole or in part from time to time for a term of five years from its grant date.

On October 17, 2011, we entered into a Securities Purchase Agreement (the “2011 Series C Purchase Agreement”) with three affiliated accredited investors in which we sold the investors a total of 10,000 newly authorized shares of $0.001 par value Series C Preferred Stock (the “Series C Preferred Stock”) at $100.00 per share, for an aggregate price of $1,000,000.  Under the terms of the 2011 Series C Purchase Agreement, we also issued warrants to the investors, pro rata to their investment amounts, to purchase an aggregate of 270,000 shares of our Common Stock at an exercise price of $2.90 per share.  Each warrant may be exercised in whole or in part from time to time for a term of five years from its grant date.

Security Ownership of Certain Beneficial Owners and Management
 
The following table sets forth certain information regarding the ownership of our Common Stock as of May 8, 2012 by: (a) each current director; (b) each executive officer; (c) all of our current executive officers and directors as a group; and (d) all those known by us to be beneficial owners of more than five percent of our Common Stock. 
 
Name (1)
 
Number of Shares Beneficially Owned (2)
   
Percentage of Shares Beneficially Owned (3)
 
5% or Greater Stockholders:
           
Cape Bear Partners, LLC (4)
    1,281,040       12.5 %
Karen Singer (5)
    2,327,823       18.5 %
Lloyd I. Miller III (6)
    2,327,823       18.5 %
John C. Backus and Todd L. Hixon Group(7)
    2,321,596       22.1 %
                 
Executive Officers and Directors:
               
Lalit Dhadphale (8)
    2,296,720       21.7 %
Patrick E. Delaney (9)
    265,283       2.6 %
Youssef Bennani (10)
    105,000       1.0 %
John C. Backus (11)
    2,321,596       22.1 %
Matthew Stecker (12)
    10,000       *  
Joseph Savarino (13)
    128,569       1.3 %
All executive officers and directors as a group
 (6 persons)
    5,127,168       46.4 %

* Less than 1.0%
 
 
 

 
- 42 -

 
 


  
(1)
The address of each officer and director is c/o HealthWarehouse.com, Inc., 7107 Industrial Road, Florence, Kentucky 41042.
 
 
(2)
This table is based upon information supplied by officers, directors and principal stockholders and Schedules 13D and 13G filed with the SEC.  Unless otherwise indicated, includes shares owned by a spouse, minor children and relatives sharing the same home, as well as the entities owned or controlled by the named person.  Also includes shares if the named person has the right to acquire those shares within 60 days after May 8, 2012, by the exercise of any warrant, stock option, convertible note or other right.  Unless otherwise indicated in the footnotes to this table and subject to community property laws where applicable, we believe that each of the stockholders named in this table has sole voting and investment power with respect to the shares indicated as beneficially owned.
 
  
(3)
Applicable percentages are based on 10,244,699 shares of Common Stock outstanding on June 8, 2012, adjusted as required by rules promulgated by the SEC.    Does not include 394,685 shares of Series B Preferred Stock outstanding on June 8, 2012, which shares are convertible into 1,973,427 shares of Common Stock.  The shares of Common Stock and shares underlying convertible preferred stock, convertible notes, and stock options or warrants are deemed outstanding for purposes of computing the percentage of the person holding such convertible preferred stock, convertible notes, and/or stock options or warrants but are not deemed outstanding for the purpose of computing the percentage of any other person.
 
 
(4)
Lynn Peppel is the Managing Member of Cape Bear Partners LLC and has sole voting and investment power over the shares owned by Cape Bear Partners LLC. Cape Bear Partners LLC’s address is 703 Solana Shores Drive, Apt 406B Cape Canaveral, FL 32920.  Does not include warrants to purchase 250,000 shares of Common Stock that are not currently exercisable.
 
 
(5)
 
Includes (i) warrants to purchase 1,148,308 shares of Common Stock, (ii) 177,379 shares of Series B Preferred Stock convertible into 886,895 shares of Common Stock, and (iii) a convertible note in the principal amount of $500,000 convertible into 292,620 shares of Common Stock.  The securities described above are owned by HWH Lending, LLC, a Delaware limited liability company (“HWH”).  Ms. Singer is the sole trustee of The Singer Children’s Management Trust (the “Trust”).  The Trust is the sole member of HWH.  As the trustee of the Trust, Ms. Singer has sole dispositive and voting power with respect to the securities owned by HWH.  Ms. Singer’s address is 212 Vaccaro Drive, Cresskill, NJ 07626.  The information in this Note 5 is based in part on information contained in the Schedule 13D/A Amendment No. 2 filed with the SEC by Karen Singer on September 9, 2011.
 
 
(6)
 
Includes (i) warrants to purchase 1,148,308 shares of Common Stock, (ii) 177,379 shares of Series B Preferred Stock convertible into 886,895 shares of Common Stock, and (iii) a convertible note in the principal amount of $500,000 convertible into 292,620 shares of Common Stock.  The securities described above are owned by Milfam I L.P., a Georgia limited partnership (“Milfam L.P.”)  Milfam LLC, an Ohio limited liability company (“Milfam LLC”) is the general partner of Milfam L.P.  Mr. Miller is the manager of Milfam LLC.  As the manager of Milfam LLC, Mr. Miller has sole dispositive and voting power with respect to the securities owned by Milfam L.P.  Mr. Miller’s address is 4550 Gordon Drive, Naples, FL 34102.  The information in this Note 6 is based in part on information contained in the Schedule 13D/A Amendment No. 2 filed with the SEC by Lloyd I. Miller, III on September 9, 2011.
 
  
(7)
 
Consists of (i) 1,956,941 shares and warrants to purchase 257,544 shares of Common Stock owned by New Atlantic Venture Fund III, L.P., a Delaware limited partnership (“NAV”), (ii) 72,708 shares and warrants to purchase 9,568 shares of Common Stock owned by New Atlantic Entrepreneur Fund III, L.P., a Delaware limited partnership (“NAE”), and (iii) 21,947 shares and warrants to purchase 2,888 shares of Common Stock owned by NAV Managers Fund, LLC, a Delaware limited liability company (“NAV Managers”).  New Atlantic Fund III, LLC, a Delaware limited liability Company (“NAF”), is the general partner of NAV and NAE.  Each of NAV, NAE and NAV Managers have shared voting and dispositive power over the shares owned by such entity.
 
 
 
 
 

 

 
- 43 -


 
 

 
   
John C. Backus is a managing member of NAV, NAE and NAF, and is a member of NAV Managers.  As such, Mr. Backus has shared voting and dispositive power over the 2,321,596 shares owned in total by NAV, NAE, and NAV Managers.
 
Todd L. Hixon is a managing member of NAV, NAE and NAF, and is a member of NAV Managers.  As such, Mr. Hixon has shared voting and dispositive power over the 2,321,596 shares owned in total by NAV, NAE, and NAV Managers.
 
Scott M. Johnson is a managing member of NAV, NAE and NAF.  As such, Mr. Johnson has shared voting and dispositive power over the 2,296,761 shares owned in total by NAV and NAE.
 
Thanasis Delistathis is a managing member of NAV, NAE and NAF.  As such, Mr. Delistathis has shared voting and dispositive power over the 2,296,761 shares owned in total by NAV and NAE.
 
As the general partner of NAV and NAE, NAF has shared voting and dispositive power over the 2,296,761 shares owned in total by NAV and NAE.
 
The business address for NAV, NAE, NAV Managers, NAF, John C. Backus, Todd C. Hixon, Scott M. Johnson and Thanasis Delistathis is 11911 Freedom Drive, Suite 1080, Reston, VA 20190.
 
The information in this Note 7 is based on the information contained in the Schedule 13D/A Amendment No. 3 filed with the SEC by the John C. Backus and Todd L. Hixon group on October 18, 2011.
 
 
(8)
 
Includes stock options to purchase 333,333 shares of Common Stock.  Does not include stock options to purchase 416,667 shares of Common Stock that are not currently exercisable.
 
(9)
Includes stock options to purchase 84,241 shares of Common Stock. Does not include stock options to purchase 33,334 shares of Common Stock that are not currently exercisable.
 
  
(10)
Includes stock options to purchase 105,000 shares of Common Stock.  Does not include stock options to purchase 75,000 shares of Common Stock that are not currently exercisable.
 
 
(11)
 
See Footnote (7) above.  Does not include stock options to purchase 45,000 shares of Common Stock that are not currently exercisable.
 
 
(12)
 
Includes stock options to purchase 10,000 shares of Common Stock.  Does not include stock options to purchase 35,000 shares of Common Stock that are not currently exercisable.
 
 
(13)
Includes stock options to purchase 10,000 shares of Common Stock.  Does not include stock options to purchase 35,000 shares of Common Stock that are not currently exercisable.
 


Related Party Transactions

Between 2009 and April 2012, the Company made advances to or on behalf of Michael E. Peppel, who was employed by the Company at the time.  He is the son of the managing member of Cape Bear Partners LLC (“Cape Bear”), which is the beneficial owner of approximately 12% of the Company’s outstanding common stock.  The advances included the unauthorized provision of fulfillment services at no charge to a business partly owned by a member of his household.  Management believes that providing these services offered a reciprocal benefit to the Company because it introduced it to doctors and customers who were not otherwise aware of the Company.  During the course of 2011, the total outstanding balance of all advances to Mr. Peppel exceeded $120,000.  The total outstanding balance of these advances was $298,707 as of December 31, 2011, $364,257 as of March 31, 2012, and $140,770 as of May 31, 2012.  Because of material weaknesses and other deficiencies in our internal controls, not all these advances were authorized in accordance with our policy on related party transactions, documented appropriately or recorded correctly in our accounting system.  As a result, the Company was not able to monitor the outstanding amount of these advances or ascertain their validity on a continuous basis.
 
 
 

 
- 44 -



 
 
The employee voluntarily resigned in April 2012 and the Company will stop providing services to the business in the second quarter of 2012.  As of May 23, 2012, he repaid $235,000, leaving a balance of $140,770 outstanding. On May 23, 2012 and May 29, 2012, he gave the Company demand notes with the following terms:  $67,074 and $73,695, respectively, payable on demand by the Company any time after December 1, 2012, with an interest rate equal to Prime as published in the Wall Street Journal on the first business day of each quarter and adjusted quarterly.  The interest rate for the quarter ending June 30, 2012 will be 3.25%.  Cape Bear has pledged 42,860 of its shares of Company common stock to secure this obligation.
 
As part of the Board’s plan to remediate the weaknesses in our internal controls and improve the quality of our policies and procedures, the Company intends to adopt a more robust formal written policy on related party transactions.
 
Lalit Dhadphale, our President and Chief Executive Officer, and Cape Bear Partners LLC, the beneficial owner of 12.3% of our Common Stock, guaranteed Old HW’s obligations under certain Old HW convertible promissory notes with an original principal value of approximately $1,200,000, which notes we assumed in connection with the Exchange. The guarantees stated that Mr. Dhadphale and Cape Bear Partners LLC each guarantee the full payment of principal and interest under the notes. The guarantees terminate with respect to each note upon the earlier of repayment of principal and interest under each note or conversion of the note to equity. In the event of note conversion, the guarantees remain in place with respect to any interest due and unpaid through the date of conversion until that interest has been paid. During the fourth quarter of 2009 and during 2010, the holders of notes in an aggregate principal amount of $1,000,000 elected to convert their notes.  The maximum principal exposure of each of Mr. Dhadphale and Cape Bear Partners LLC pursuant to the guarantees as of December 31, 2010 was $200,000, plus interest. On January 5, 2011, the remaining convertible note balance of $200,000 was converted plus all accrued interest was paid eliminating any exposure for each of Mr. Dhadphale and Cape Bear Partners LLC pursuit to the guarantees.

In connection with the creation and support to the Company from the state of Kentucky, Lalit Dhadphale and Cape Bear Partners LLC received 250,000 options and 250,000 warrants, respectively.  To provide credit support for the development loans from Kentucky, both Lalit Dhadphale and Cape Bear Partners LLC have planned to enter into a liquidity facility that will cover the Company’s repayment obligations.  The options and warrants respectively granted will become 100% vested immediately upon execution of a liquidity facility by the Company with both Lalit Dhadphale and Cape Bear, satisfactory to the Company in form and substance.

On December 15, 2009, we entered into a Loan and Security Agreement (the “Loan Agreement”) with HWH Lending LLC, a Delaware limited liability company (“HWH”).  Under the terms of the Loan Agreement, we borrowed $515,000 from HWH on December 15, 2009, and we borrowed an additional $500,000 on May 3, 2010 (together, the “Loans”).  The proceeds of the Loans were used by us for working capital purposes.  The Loans were evidenced by promissory notes (the “Notes”), and bore interest at the rate of 12% per annum, payable at maturity.  The maturity date of each Loan was one year from the date of the Loan.  The Loans could be prepaid in whole or in part at any time by us without penalty, upon 15 days notice.  Lalit Dhadphale, our President and Chief Executive Officer, personally guaranteed our payment and other obligations under the Loan Agreement and the Notes.  Mr. Dhadphale also entered into a Lock-up Agreement (“Lock-up”) with HWH prohibiting Mr. Dhadphale from selling or transferring 625,000 shares of our common stock until the Loans are repaid in full, subject to certain exceptions, such as gifts.  We prepaid the Loans in full on November 8, 2010, and Mr. Dhadphale’s personal guaranty and the Lock-Up were terminated.
 
Jason Smith was the beneficial owner of 1,369,333 shares, or 12.8% of our Common Stock, of which 33,333 shares were beneficially owned by him directly, and 1,336,000 shares were beneficially owned by Rock Castle Holdings, LLC (“Rock Castle”).  As the Manager of Rock Castle, Jason Smith has sole voting and dispositive power over the shares owned by Rock Castle and, as such, was deemed to beneficially own such shares.  On September 2, 2011, the Company purchased 1,179,212 shares of its Common Stock from Rock Castle Holdings, LLC, a more than 10% stockholder of the Company, which constituted all of the outstanding shares of Common Stock owned by Rock Castle.  The purchase price was $2.90 per share for a total purchase price of $3,419,715.  As explained in Item 3, “Legal Proceedings,” Mr. Smith is currently adverse to the Company in a number of state court claims.  The Company has denied each claim and filed for a motion to dismiss all such claims.

The Company occupied approximately 16,000 square feet of office and storage space under a Commercial Sublease Agreement with Masters Healthcare, LLC, an entity that is also controlled by Jason Smith. The sublease expired March 2011, and was renewed on a month to month basis until July 2011. The rent expense under this sublease for the years ended December 31, 2011 and 2010 was $84,750 and $113,004.
 
 

 
 
- 45 -


 

 

Jason Smith is also the son of Dennis Smith, the controlling stockholder of Masters Pharmaceutical, Inc., one of the Company’s principal suppliers. We purchased from Masters Pharmaceutical, Inc., $618,768 and $959,847 of supplies, representing approximately 11% and 29% of total purchases during the years ended December 31, 2011 and 2010, respectively. Accounts payable due to Masters Pharmaceutical, Inc. at December 31, 2011 and 2010 was $0 and $215,858, respectively. At December 31, 2010, we also had accrued interest expense due to Masters Pharmaceutical, Inc. of $17,000.

For the year ended December 31, 2011 and 2010, sales to Masters Pharmaceuticals were approximately 1.56% and 8.76%, respectively, of our net sales.

On November 8, 2010, we entered into a Securities Purchase Agreement (the “Purchase Agreement”) with four accredited investors, including HWH Lending, LLC (“HWH”) and Milfam I, L.P. (“Milfam”).  Under the terms of the Purchase Agreement, we sold a total of 164,114 newly authorized shares of $0.001 par value Series B preferred stock (the “Series B Preferred Stock”) to each of HWH and Milfam at $9.45 per share, for an aggregate price of approximately $1,551,000.  Each share of the Series B Preferred Stock may be converted at any time, in whole or in part, into five shares of our Common Stock, as adjusted.  As a result of this transaction, each of HWH and Milfam became a beneficial owner of more than 10% of our Common Stock.  HWH and Milfam also entered into a separate Loan and Security Agreement dated November 8, 2010 (the “2010 Loan Agreement”).  Under the terms of the 2010 Loan Agreement and the Purchase Agreement, we sold convertible promissory notes to each of HWH and Milfam in the aggregate principal amount of $1,000,000 (the “Convertible Notes”). The Convertible Notes bear interest at the rate of 7% per annum compounded annually.  The principal amount and all accrued interest on the Convertible Notes are payable on December 31, 2012, or earlier on an event of default or a sale or liquidation of the Company.  The principal amount and accrued interest on the Convertible Notes may be converted at any time into shares of Series B Preferred Stock at a conversion price of $9.45 per share, as adjusted. The net proceeds from these transactions were used to expand our online presence, upgrade our technology infrastructure, and pay existing indebtedness and accrued expenses, and for general working capital purposes.  Under the terms of the Purchase Agreement, we also issued warrants to each of HWH and Milfam, to purchase 585,808 shares of our Common Stock at an exercise price of $3.00 per share.  Each warrant may be exercised in whole or in part and from time to time for a term of five years from its grant date.  The warrants contain anti-dilution and purchase price adjustment provisions.  The warrants are transferable in whole or in part, so long as the transfers comply with applicable securities laws.
 
In connection with the relocation of our facilities to the Commonwealth of Kentucky (the “State”), we are eligible to receive various economic incentives from the State, including an economic development loan of $500,000 (the “Development Loan”), which we may become obligated to repay in whole or in part depending on certain criteria such as the level of hiring of additional employees.  In order to make the Development Loan, the State is requiring that the repayment of the Development Loan be secured by various types of collateral.  Cape Bear Partners, LLC, a more than 10% stockholder of the Company, has agreed to personally provide certain credit support for the Company’s obligations under the Development Loan, including a pledge of shares of Company Common Stock (the “Pledge”).  In consideration of the Pledge, on August 31, 2011, we issued to Cape Bear a warrant to purchase 250,000 shares of our Common Stock at an exercise price of $2.90 per share.  The warrant will become vested and exercisable on the effective date of the Pledge, and is for a term of ten years from the grant date.

On September 2, 2011, we entered into a Loan and Security Agreement (the “2011 Loan Agreement”) with HWH and Milfam. Under the terms of the 2011 Loan Agreement, we borrowed $1,500,000 from each of HWH and Milfam for a total of $3,000,000 (the “2011 Loans”).  The 2011 Loans are evidenced by non-convertible, secured promissory notes, bearing interest at 7% per annum, payable at maturity.  The principal amount and all accrued interest on the 2011 Loans are payable on January 15, 2013, or earlier on an event of default or a sale or liquidation of the Company.  In connection with 2011 Loans, we also granted to each of HWH and Milfam a warrant to purchase 250,000 shares of our Common Stock at a purchase price of $2.90 per share.  Each warrant may be exercised in whole or in part from time to time for a term of five years from its grant date.  We used the proceeds from the 2011 Loans to purchase all 1,179,212 shares of our Common Stock owned by Rock Castle.

On October 17, 2011, we entered into a Securities Purchase Agreement (the “2011 Series C Purchase Agreement”) with New Atlantic Venture Fund III, L.P. and two affiliates (“NAV”), a more than 10% stockholder of the Company, in which we sold NAV a total of 10,000 newly authorized shares of $0.001 par value Series C Preferred Stock (the “Series C Preferred Stock”) at $100.00 per share, for an aggregate price of $1,000,000.  The Series C Preferred Stock has voting rights equal to one vote for each share held, has a liquidation preference equal to its purchase price, has redemption request rights available on or after January 15, 2013, are non-convertible and does not pay dividends. Under the terms of the 2011 Series C Purchase Agreement, we also issued warrants to the NAV entities, pro rata to their investment amounts, to purchase an aggregate of 270,000 shares of our Common Stock at an exercise price of $2.90 per share.  Each warrant may be exercised in whole or in part from time to time for a term of five years from its grant date.  We used the proceeds from the sale of the Series C Preferred Stock to prepay accrued interest and principal on the 2011 Loans.
 
 
 

 
 
- 46 -

 
 

 

Although we have not adopted formal procedures for the review, approval or ratification of transactions with related persons, we have a general policy that such transactions should only be entered into if they are on terms that, on the whole, are no more favorable, than those from unaffiliated third parties and their approval is in accordance with applicable law.  This general policy requires the approval of our board of directors.  As discussed in Part II-Item 9A.  "Controls and Procedures--Plans For Remediation of Material Weakness,"  we are in the process of developing a remediation plan for the identified material weaknesses and we are evaluating what additional policies and procedures may be necessary.  We expect to adopt a formal written policy on transactions with related persons in connection with this process.
 
Director Independence

Our board of directors has determined that Youssef Bennani and Joseph Savarino are “independent” within the meaning of Rule 5605(a)(2) of the National Association of Securities Dealers’ Marketplace Rules of the Nasdaq Stock Market (the “NASDAQ Rules”), and that they are also “independent” for purposes of Rule 10A-3 of the Exchange Act. Lalit Dhadphale, John C. Backus and Matthew Stecker is not an “independent” within the meaning of Rule 5605(a)(2) of the NASDAQ Rules.

In making each of these independence determinations, our board of directors considered and broadly assessed, from the standpoint of materiality and independence, all of the information provided by each director in response to detailed inquiries concerning the director’s independence and any direct or indirect business, family, employment, transactional or other relationship or affiliation of such director with our company.


The following table presents fees for professional services rendered by the Company’s principal accountant.  Marcum LLP, for the audit of the Company’s annual consolidated financial statements for the years ended December 31, 2011, and  2010, and fees billed for other services rendered by our principal accountants during those periods.
 
   
Year Ended
   
Year Ended
 
   
December 31, 2011
   
December 31, 2010
 
             
Audit Fees (1)
  $ 138,631     $ 118,178  
Audit Related Fees (2)
    -       -  
Tax Fees (3)
    -       -  
All Other Fees (4)
    -       -  
 
(1)           Audit fees were principally for audit work performed on our annual financial   statements and review of our interim financial statements.

(2)           There were no “audit-related services” during the period.

(3)           There were no “tax services” during the period.

(4)           There were no “other services” during the period.

An audit committee was formed on April 8, 2010 (see item 10 of this report). During the years ended December 31, 2011 and 2010, the Audit Committee met to review and approve the filing of forms 10K and 10Q. All audit and non-audit services performed by Marcum were pre-approved by the Board of Directors.
 
 
 

 
 
- 47 -



 

(a)           Exhibits

Exhibit No.
 
Description
     
2.1
 
Share Exchange Agreement, dated May 14, 2009, between Clacendix, Inc. and HealthWarehouse.com, Inc. (1)
     
2.2
 
Asset Purchase Agreement, dated February 14, 2011, among Hocks Acquisition Corporation, and Hocks Pharmacy, Inc. and its shareholders (16)
     
2.3
 
Merger Agreement dated February 14, 2011, among HealthWarehouse.com, Inc., Hocks Acquisition Corporation, Hocks Pharmacy, Inc. and its shareholders, and Hocks.com, Inc. (16)
     
3.1
 
Certificate of Incorporation of the Company, as amended through December 31, 2005 (2)
     
3.2
 
Certificate of Amendment of the Certificate of Incorporation of the Company, filed on January 4, 2008 (3)
     
3.3
 
Certificate of Amendment of the Certificate of Incorporation of the Company, filed on July 14, 2008 (4)
     
3.4
 
Certificate of Amendment of the Certificate of Incorporation of the Company, filed on July 31, 2009 (5)
     
3.5
 
Certificate of Amendment to the Company’s Certificate of Incorporation filed on July 16, 2010 (13)
     
3.6
 
Certificate of Designation of Preferences, Rights and Limitations of Series B Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law (14)
     
3.7
 
Amended and Restated By-Laws of the Company (14)
     
3.8
 
Certificate of Designation of Preferences, Rights and Limitations of Series C Preferred Stock Pursuant to Section 151 of the Delaware General Corporation Law, filed on October 17, 2011 (21)
     
4.1
 
Form of Old HW Convertible Promissory Note (11)
     
4.2
 
Senior Secured Promissory Note dated December 15, 2009 in the principal amount of $515,000 payable by the Company to the order of HWH Lending, LLC (7)
     
4.3
 
Senior Secured Promissory Note dated May 3, 2010 in the principal amount of $500,000, payable by the Company to the order of HWH Lending, LLC (12)
     
4.4
 
Warrant to Purchase 156,250 Shares of the Common Stock of HealthWarehouse.com, Inc. dated November 8, 2010 and Issued to HWH Lending, LLC, as Lender  (17)
     
4.5
 
Warrant to Purchase 156,250 Shares of Common Stock of HealthWarehouse.com, Inc. dated November 8, 2010 and issued to HWH Lending, LLC as Lender  (17)
     
4.6
 
Warrant to Purchase 156,250 Shares of Common Stock of HealthWarehouse.com, Inc. dated November 8, 2010 and issued to Milfam I L.P.  (17)
     
4.7
 
Warrant to Purchase 156,250 Shares of Common Stock of HealthWarehouse.com, Inc. dated November 8, 2010 and issued to Milfam I L.P.  (17)
     
4.8
 
Form of Common Stock Purchase Warrant (14)

 
 

 
 
- 48 -

 

 

Exhibit No.
  Description
     
4.9
 
Senior Secured Convertible Promissory Note dated November 8, 2010 in the amount of $500,000 payable by the Company to the order of Milfam I L.P. (14)
     
4.10
 
Senior Secured Convertible Promissory Note dated November 8, 2010 in the amount of $500,000 payable by the Company to the order of HWH Lending, LLC (14)
     
4.11
 
Senior Secured Promissory Note dated September 2, 2011 in the principal amount of $1,500,000 payable by the Company to the order of HWH Lending, LLC. (20)
     
4.12
 
Warrant to Purchase 250,000 Shares of the Common Stock of HealthWarehouse.com, Inc., dated September 2, 2011 and Issued to HWH Lending, LLC. (20)
     
4.13
 
Senior Secured Promissory Note dated September 2, 2011 in the principal amount of $1,500,000 payable by the Company to the order of Milfam I, L.P. (20)
     
4.14
 
Warrant to Purchase 250,000 shares of the Common Stock of Healthwarehouse.com, Inc. dated September 2, 2011 and issued to Milfam I, L.P. (20)
     
4.15
 
Form of Common Stock Purchase Warrant. (21)
     
10.1
 
1998 Stock Option Plan of the Company (6) +
     
10.2
 
2000 Stock Option Plan of the Company (2) +
     
10.3
 
2006 Stock Option Plan of the Company (2) +
     
10.4
 
Form of Incentive Stock Option Agreement under 2006 Stock Option Plan of the Company (8) +
     
10.5
 
Old HW Convertible Promissory Note Subscription Agreement (11)
     
10.6
 
Old HW Convertible Promissory Note and Warrants to Purchase Common Stock Subscription Agreement (11)
     
10.7
 
2009 Incentive Compensation Plan (9) +
     
10.8
 
Form of Stock Option Agreements under 2009 Incentive Compensation Plan (11) +
     
10.9
 
Loan and Security Agreement dated December 15, 2009 among HealthWarehouse.com, Inc. and Hwareh.com, Inc. as Borrowers, and HWH Lending LLC, as Lender (7)
     
10.10
 
Securities Purchase Agreement dated November 8, 2010 (14)
     
10.11
 
Loan and Security Agreement dated November 8, 2010 among HealthWarehouse.com, Inc. and Hwareh.com, Inc., as Borrowers, and HWH Lending, LLC and Milfam I L.P. as Lenders (14)
     
10.12
 
Commercial Sublease Agreement between the Company and Masters Healthcare, LLC dated effective April 1, 2008, as amended by a First Amendment dated effective June 1, 2009 (15)
     
10.13
 
Securities Purchase Agreement dated August 3, 2011 (18)
     
10.14
 
Investor Rights Agreement dated August 3, 2011 (18)
     
10.15
 
Indemnification Agreement dated August 3, 2011 (18)
 
 
 
 
 
 
 
- 49 -

 
 
 

 
Exhibit No.   Description
     
10.16
 
Lease agreement dated June15, 2011 between the Company and the landlord for 7107 Industrial Road Florence, Kentucky(19)
     
10.17
 
Loan and Security Agreement dated September 2, 2011 among HealthWarehouse.com, Inc., Hwareh.com, Inc. and Hocks.com, Inc., as Borrowers, and HWH Lending LLC, and Milfam I, L.P., as Lenders (20)
     
10.18
 
Stock Purchase Agreement dated September 2, 2011 between the Company and Rock Castle Holdings, LLC (20)
     
10.19
 
Securities Purchase Agreement dated October 17, 2011 (21)
     
10.20
 
Amendment No. 1 to Investor Rights Agreement dated October 17, 2011 (21)
     
10.21
 
Form of Subscription Agreement for Common Stock (21)
     
21.1
 
     
31.1
 
     
31.2
 
     
32.1
 
     
32.2
 

       *                 Filed herewith.

       +                 Denotes Management Compensatory Plan or Contract.
 
 
(1)  
Incorporated by reference to the Company’s Current Report on Form 8-K filed on May 15, 2009.

(2)  
Incorporated by reference to the Company’s Annual Report on Form 10-K SB filed on March 29, 2006.

(3)  
Incorporated by reference to the Company’s Annual Report on Form 10-K filed on March 27, 2009.

(4)  
Incorporated by reference to the Company’s Annual Report Amendment on Form 10-KA filed on May 14, 2009.

(5)  
Incorporated by reference to the Company’s Current Report on Form 8-K filed on August 6, 2009.

(6)  
Incorporated by reference to the Company’s Registration Statement on Form S-8 filed on April 22, 1999.

(7)  
Incorporated by reference to the Company’s Current Report on Form 8-K filed on December 17, 2009.

 
 
 
 
 
 
 
- 50 -

 
 
 

 

(8)  
Incorporated by reference to the Company’s Current Report on Form 8-K filed on November 14, 2006.

(9)  
Incorporated by reference to the Company’s Current Report Amendment on Form 8-KA filed on May 26, 2009.

(10)  
Incorporated by reference to the Company’s Current Report Amendment on Form 8-KA filed on August 17, 2009.

(11)  
Incorporated by reference to the Company’s Annual Report on Form 10-K filed on April 15, 2010.

(12)  
Incorporated by reference to the Company’s Current Report on Form 8-K filed on May 5, 2010.

(13)  
Incorporated by reference to the Company’s Current Report on Form 8-K filed on July 21, 2010.
 
(14)  
Incorporated by reference to the Company’s Current Report on Form 8-K filed on November 12, 2010.

(15)  
Incorporated by reference to the Company’s Amendment No. 1 on Form 10-K/A filed on November 30, 2010.

(16)  
Incorporated by reference to the Company’s Current Report on Form 8-K filed on February 16, 2011.

(17)  
Incorporated by reference to the Company’s Annual Report on Form 10-K filed on April 15, 2011.

(18)  
Incorporated by reference to the Company’s Current Report on Form 8-K filed on August 8, 2011.

(19)  
Incorporated by reference to the Company’s Quarterly Report on Form 10-Q filed on August 15, 2011.

(20)  
Incorporated by reference to the Company’s Current Report on Form 8-K filed on September 6, 2011.

(21)  
Incorporated by reference to the Company’s Current Report on Form 8-K filed on October 20, 2011.

 
 
 
 

 
 
- 51 -


 
 
 
SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Dated: June 21, 2012
HEALTHWAREHOUSE.COM, INC.
 
 
By:   /s/ Lalit Dhadphale                                                               
    Lalit Dhadphale
    President and Chief Executive Officer
    (principal executive officer)
 
 
 
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
 
Name
 
Title
 
Date
         
         
 /s/  Lalit Dhadphale                                                           
        Lalit Dhadphale
 
President, Chief Executive Officer and Director
(principal executive officer)
 
June  21, 2012
         
         
 /s/  Patrick E. Delaney                                                       
       Patrick E. Delaney
 
Chief Financial Officer, Treasurer, and Secretary
(principal financial and accounting officer)
 
June 21, 2012
         
         
 /s/  John Backus                                                                  
        John Backus
 
 
Director
 
 
June 21, 2012
         
         
 /s/  Youssef Bennani                                                           
        Youssef Bennani
 
 
Director
 
 
June 21, 2012
         
         
 /s/  Matthew Stecker                                                           
       Matthew Stecker
 
 
Director
 
 
June 21, 2012
         
         
 /s/  Joseph Savarino                                                           
        Joseph Savarino
 
 
Director
 
 
June 21, 2012
 
 
 
 
 
 
 

 
- 52 -




 
 
 
 
 
 
 
 
 
 
 
- 53 -

 
 
 
 
 
 
 

To the Audit Committee of the Board of Directors and Stockholders of
Healthwarehouse.com, Inc.

We have audited the accompanying consolidated balance sheets of Healthwarehouse.com, Inc. and Subsidiaries (the “Company”) as of December 31, 2011 and 2010, and the related consolidated statements of operations, stockholders’ (deficiency) equity and cash flows for the years then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Healthwarehouse.com, Inc. and Subsidiaries as of December 31, 2011 and 2010, and the results of their operations and their cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As more fully described in Note 2, the Company has incurred significant losses and needs to raise additional funds to meet its obligations and sustain its operations.  These conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.



/s/ Marcum LLP                                                 
      Marcum LLP
      New York, NY
      June 21, 2012
 
 
 
 
 

 
- 54 -



 
HEALTHWAREHOUSE.COM, INC. AND SUBSIDIARIES

Assets
 
   
December 31, 2011
   
December 31, 2010
 
Current assets
           
Cash
  $ 40     $ 1,397,583  
Accounts receivable, net
    220,626       604,524  
Inventory, net
    553,897       374,519  
Employee advances
    298,707       51,429  
Prepaid expenses and other current assets
    54,480       126,708  
      Total current assets
  $ 1,127,750     $ 2,554,763  
Property and equipment, net
    943,849       320,328  
Website development costs, net of accumulated amortization of $200,396
      and $139,475, respectively
    -       60,921  
Intangible assets, net of accumulated amortization of $90,794 as of
     December 31, 2011
    602,541       -  
                 
          Total  assets
  $ 2,674,140     $ 2,936,012  
Liabilities and Stockholders’ (Deficiency) Equity
 
Current liabilities
               
Accounts payable – trade
  $ 1,547,657     $ 807,481  
Accounts payable – related parties
    14,209       232,858  
Cash overdraft
    239,567       -  
Accrued expenses and other current liabilities
    549,011       240,098  
Current portion of capital lease
    3,346       -  
    Convertible notes, net of deferred debt discount of $275,388 and $9,658, respectively
    724,612       215,342  
     Note payable and other advances – related parties
    453,812       -  
Total current liabilities
  $ 3,532,214     $ 1,495,779  
                 
Long term liabilities
               
     Convertible notes payable, net of deferred debt discount of $600,354 as of December 31, 2010
    -       399,646  
     Notes payable, net of deferred debt discount of $576,741 as of
           December 31, 2011
    1,423,259       -  
     Long term portion of capital lease
    9,201       -  
         Total long term liabilities
    1,432,460       399,646  
         Total liabilities
  $ 4,964,674     $ 1,895,425  
                 
Commitments and contingencies
               
Redeemable preferred stock – Series C ; net of discount $433,606 as of December 31, 2011; 10,000 designated Series C: 10,000 issued and outstanding  as of December 31, 2011(aggregate liquidation preference $1,000,000)
    566,394       -  
                 
Stockholders’ (deficiency) equity
               
Preferred Stock par value $.001 per share; authorized 1,000,000 shares; issued and outstanding as of  December 31, 2011 and 2010 as follows:
               
Convertible preferred stock - Series A –200,000 shares designated Series A; no  shares issued and outstanding
    -       -  
Convertible preferred stock - Series B –625,000 shares designated Series B; 368,862 and 365,265  shares issued, and outstanding, respectively (aggregate liquidation preference $3,729,773 and $3,451,754, respectively)
    369       365  
Common stock – par value $.001 per share; authorized 50,000,000 shares;
11,283,830 and 10,278,934 shares issued, respectively and 10,104,618 and 10,278,934 shares outstanding, respectively
      11,284         10,279  
Additional paid-in capital
    15,110,343       9,540,036  
Treasury stock, at cost, 1,179,212 shares as of December 31, 2011
    (3,419,715 )     -  
Accumulated deficit
    (14,559,209 )     (8,510,093 )
     Total stockholders’(deficiency) equity
    (2,856,928 )     1,040,587  
Total liabilities and stockholders’  (deficiency) equity
  $ 2,674,140     $ 2,936,012  

 
The accompanying notes are an integral part of these consolidated financial statements.
 
 
 

 
- 55 -


 

 

HEALTHWAREHOUSE.COM, INC. AND SUBSIDIARIES

   
For the Year Ended
December 31, 2011
   
For the Year Ended
December 31, 2010
 
             
Net sales
  $ 10,363,293     $ 5,691,765  
                 
Cost of sales
    5,845,525       3,450,021  
Gross profit
    4,517,768       2,241,744  
                 
Operating expenses:
               
                 
   Selling, general and administrative expenses
    9,246,431       5,303,617  
                 
Loss from operations
    (4,728,663 )     (3,061,873 )
                 
Other income (expense):
               
Gain on settlement  of accounts payable
    32,210       -  
Interest income
    4,166       642  
Interest expense
    (1,021,112 )     (679,330 )
Gain on litigation settlement
    -       48,887  
Other income
    1,200       -  
    Total other expense
    (983,536 )     (629,801 )
                 
Net loss
  $ (5,712,199 )   $ (3,691,674 )
                 
Contractual dividends
    (244,001 )     (33,992 )
Deemed dividends
    (92,916 )     (1,666,967 )
                 
Loss attributable to common stockholders
  $ (6,049,116 )   $ (5,392,633 )
                 
Per share data:
               
Net loss - basic and diluted
  $ (0.55 )   $ (0.37 )
Contractual dividends
  $ (0.02 )   $ (0.00 )
Deemed dividends
  $ (0.01 )   $ (0.17 )
Net loss attributable to common stockholders – basic and diluted
  $ (0.58 )   $ (0.54 )
                 
Weighted average number of common shares outstanding - Basic and diluted
    10,397,667       10,068,575  


The accompanying notes are an integral part of these consolidated financial statements.
 
 

 
- 56 -


 
Healthwarehouse.com, Inc. and Subsidiaries
For the Years Ended December 31, 2011 and 2010
 
   
Convertible
Series A Preferred
 
Convertible
Series B Preferred
  Common   Treasury                
    Shares   Amount   Shares   Amount   Shares   Amount   Shares   Amount    
Additional
Paid-In
Capital
 
Accummulated
Deficit
   
Total
Stockholders’
Deficiency)
Equity
 
Balances, December 31, 2009
    107,501     108     -     -     9,881,767     9,882     -     -     2,735,851     (3,117,460 )     (371,619 )
                                                                       
Conversion of Series A Preferred stock to common stock
    (107,501 )   (108 )               53,752     54                 54             -  
                                                                       
Issuance of Series B Preferred stock, net of costs
                365,265     365